胸膜肺炎放线杆菌异源保护抗原肽筛选及ApxIV体外表达
|
摘要
胸膜肺炎放线杆菌是引起猪传染性胸膜肺炎放线杆菌疾病的主要病原菌，该病是世界范围内流行并严重危害养猪业的重要传染病。胸膜肺炎放线杆菌具有多个血清型，其致病力和免疫原性各不相同，主要血清型之间缺乏免疫交叉保护，影响了其疫苗的开发。我们先前的研究通过MALDI-ToF质谱鉴定出了六个共同抗原蛋白，单链DNA结合蛋白（PA-Ssb）、噬菌体休克蛋白A（PA-PspA）、甘油醛-3磷酸脱氢酶（PA-GAPDH）、丙酮酸激酶（PA-Pk）、丝氨酸羟甲基转移酶（PA-Shmt）以及天冬氨酸转氨酶（PA-Ast）。以痤疮丙酸杆菌参考菌株设计引物克隆并测序了以上六个蛋白，通过Genebank以及其他生物信息学数据库对其进行了分析，并上传至Genebank数据库。构建了六个抗原蛋白的原核表达载体pGEX-PA-Ssb、pGEX-PA-Pspa、pGEX-PA-GAPDH、pGEX-PA-Pk、pGEX-PA-Shmt和pGEX-PA-Ast，并表达纯化出了六个抗原蛋白的GST融合蛋白。通过小鼠模型免疫并以胸膜肺炎放线杆菌血清1型和5a型感染，分别得到免疫保护率达到（对血清1型）20%（PA-GAPDH）至80%（PA-Ssb）和（对血清5a型）10%（PA-Ast）至60%（PA-Ssb）。免疫保护作用最佳的抗原蛋白PA-Ssb与胸膜肺炎放线杆菌多个血清型均具有较高同源性的两段短肽，PH1（N`-AKNNSSGAGNSKDWGGN-C`）与ApxIV毒素同源，PH2（N`-VIESLSKG-C`）与ZnuA基因同源。人工合成的PH1和PH2短肽与胸膜肺炎放线杆菌多个血清型抗体均有较强的抗原抗体反应，其中PH1的反应较强。通过构建胸膜肺炎放线杆菌Nanoluc荧光素酶突变株，证明这一新型荧光素酶可以在胸膜肺炎放线杆菌内表达并催化Furimazine底物发光，是一种新型的报告基因。为了鉴定ApxIV毒素的调控子基因，通过基因工程方法构建了胸膜肺炎放线杆菌血清15型荧光突变库，采用IVIS系统对2万个以上的突变株进行了荧光筛选，没有筛选出有效的发光克隆。胸膜肺炎放线杆菌在体外培养条件下，其毒素ApxIV可以通过SDS-PAGE、免疫印迹、MALDI-ToF质谱、荧光定量PCR等方法检测出其基因的转录与表达。其表达受到培养条件不同以及钙离子浓度不同的影响。在含有5mM钙离子的增强型PPLO培养基中ApxIV的表达水平最高。本研究初步摸索了胸膜肺炎放线杆菌异源疫苗开发的一条途径，并首次以多种方法证明ApxIV毒素的体外表达。为今后胸膜肺炎放线杆菌的新型疫苗开发以及重要毒力因子的研究提供了一定基础。
Actinobacillus pleuropneumoniae is the causative agent of acute and chronicpleuroneumonia that is responsible for substantial morbidity and mortality in the pigindustry. New improved vaccines that can protect against all serotypes and preventcolonization are required. In a previous study we showed that whole cells ofPropionibacterium acnes protected pigs from A. pleuropneumoniae serotype1and5and, there are common antigens between P.acnes and A.pleuropneumoniae, therefore,the basis for a promising heterologous vaccine. The aim of this study was to analysisthose protein antigens of P. acnes responsible for protection against A.pleuropneumoniae infection. Six P. acnes protein antigens that were recognized duringour priory study by sera raised against A. pleuropneumoniae were identified by2-DEand immunoblotting. Recombinant versions of all P. acnes proteins gave partialprotection (10-80%) against A. pleuropneumoniae serotype1and/or5infection in amouse challenge model. The best protection (80%serotype1;60%serotype5) wasobtained using recombinant P. acnes single-stranded DNA-binding protein. In part,protection against A. pleuropneumoniae infection may be mediated by small peptidesequences present in P. acnes single-stranded DNA-binding protein that arecross-reactive with those present in the A. pleuropneumoniae-specific RTX toxinApxIV and the zinc-binding protein ZnuA. The results suggest that P. acnes may be auseful vaccine to protect against different serotypes ofA. pleuropneumoniae.
Nanoluc is a newly reported luciferase which catalysis furimazine substrate andglow luminescence100times stronger than commonly used firefly luciferase. It couldbe used as a reporter in mammalian cell. In this study, we are trying to integrate theNluc into of Actinobacillus pleuropneumoniae serotype15(HS143) genome under thecontrol of sodC promoter by construct a homologous recombination reporter plasmid and a mutant strain to evaluate if this new luciferase could expression and detect in A.pleuropneumoniae. Mutant strain APPS15::SodCNK cells PBS dilution andfurimazine substrate solution mixture could glow luminescence and detect by96wellsplate reader. Detect limitation is500CFU per well (1:50diluted substrate) or1:5,000diluted substrate (5*107CFU per well). Luminescence signal count will slowlyclimbed to the top in120minutes after sample loaded with NanoGlo buffer dilutedsubstrate. Another METK buffer diluted substrate reaction reach to signal top in60minutes and the signal variation is bigger than NanoGlo buffer. Single colonies placedon agar plate sprayed with substrate solution could be detect with IVIS imagingsystem, available for detect reporter gene expression. Our results indicate thatNanoluc luciferase could express in A. pleuropneumoniae and the luminescence ofthat could be detected by plate reader (suspension cells) or IVIS imaging system(colony) after catalysis furimazine substrate.
ApxIV is one of the four A. pleuropneumoniae RTX toxin, generally consideredApxIV is unique only in the in vivo expression of A. pleuropneumoniae toxins. Theexistence of ApxIV has played an important role on A. pleuropneumoniae virulenceeffecting. Recent studies reported by gene chip and two-dimensional electrophoresisand mass spectrometry in the detection of a large number of genes or proteins isdetected in vitro transcription and protein ApxIV exist, but not specifically for theexpression of ApxIV further understanding. To confirm this conclusion, we used A.pleuropneumoniae serotype1,8and15were cultured in vitro, using reversetranscription PCR, quantitative PCR, SDS-PAGE, Western Blot and MALDI massspectrometry and other methods, from transcription, protein level and theantigen-antibody reaction proved that the ApxIV expression under in vitro cultureconditions. A. pleuropneumoniae in vitro expression under different conditions isquite different, with the culture medium and the calcium ion concentration. Under theconditions of PPLO broth contains L-cysteine hydrochloride, L-cysteinehydrochloride, glucose, Tween-80,5mM calcium, it can be detected the highestApxIV protein bands. Different concentrations of calcium ions on ApxIV protein leveldetection have an important influence, but weaker effect on the transcriptional level. Therefore, we speculate that calcium may be an important regulatory factor ApxIVposttranslational modification.
In this study, cloning and expression of the six common antigen proteins betweenA. pleuropneumoniae and P. acnes and screen out two small peptides fragment of aprotein is a potential vaccine candidate, from the preliminary interpretation of theprotein levels of heterologous P, acnes immune protection Actinobacilluspleuropneumoniae infection mechanism. For the first time verified for the newluciferase Nanoluc expression and work effectively in A. pleuropneumoniae, prove itcan be a regulation studies tool and provides a new and convenient research method.From multiple angles proved A. pleuropneumoniae important virulence factor ApxIVexpression in vitro, initially discussed its expression regulation mechanism for thefurther study of this virulence factor and some help on A. pleuropneumoniaepathogenicity study and vaccine development.
Actinobacillus pleuropneumoniae is the causative agent of acute and chronicpleuroneumonia that is responsible for substantial morbidity and mortality in the pigindustry. New improved vaccines that can protect against all serotypes and preventcolonization are required. In a previous study we showed that whole cells ofPropionibacterium acnes protected pigs from A. pleuropneumoniae serotype1and5and, there are common antigens between P.acnes and A.pleuropneumoniae, therefore,the basis for a promising heterologous vaccine. The aim of this study was to analysisthose protein antigens of P. acnes responsible for protection against A.pleuropneumoniae infection. Six P. acnes protein antigens that were recognized duringour priory study by sera raised against A. pleuropneumoniae were identified by2-DEand immunoblotting. Recombinant versions of all P. acnes proteins gave partialprotection (10-80%) against A. pleuropneumoniae serotype1and/or5infection in amouse challenge model. The best protection (80%serotype1;60%serotype5) wasobtained using recombinant P. acnes single-stranded DNA-binding protein. In part,protection against A. pleuropneumoniae infection may be mediated by small peptidesequences present in P. acnes single-stranded DNA-binding protein that arecross-reactive with those present in the A. pleuropneumoniae-specific RTX toxinApxIV and the zinc-binding protein ZnuA. The results suggest that P. acnes may be auseful vaccine to protect against different serotypes ofA. pleuropneumoniae.
Nanoluc is a newly reported luciferase which catalysis furimazine substrate andglow luminescence100times stronger than commonly used firefly luciferase. It couldbe used as a reporter in mammalian cell. In this study, we are trying to integrate theNluc into of Actinobacillus pleuropneumoniae serotype15(HS143) genome under thecontrol of sodC promoter by construct a homologous recombination reporter plasmid and a mutant strain to evaluate if this new luciferase could expression and detect in A.pleuropneumoniae. Mutant strain APPS15::SodCNK cells PBS dilution andfurimazine substrate solution mixture could glow luminescence and detect by96wellsplate reader. Detect limitation is500CFU per well (1:50diluted substrate) or1:5,000diluted substrate (5*107CFU per well). Luminescence signal count will slowlyclimbed to the top in120minutes after sample loaded with NanoGlo buffer dilutedsubstrate. Another METK buffer diluted substrate reaction reach to signal top in60minutes and the signal variation is bigger than NanoGlo buffer. Single colonies placedon agar plate sprayed with substrate solution could be detect with IVIS imagingsystem, available for detect reporter gene expression. Our results indicate thatNanoluc luciferase could express in A. pleuropneumoniae and the luminescence ofthat could be detected by plate reader (suspension cells) or IVIS imaging system(colony) after catalysis furimazine substrate.
ApxIV is one of the four A. pleuropneumoniae RTX toxin, generally consideredApxIV is unique only in the in vivo expression of A. pleuropneumoniae toxins. Theexistence of ApxIV has played an important role on A. pleuropneumoniae virulenceeffecting. Recent studies reported by gene chip and two-dimensional electrophoresisand mass spectrometry in the detection of a large number of genes or proteins isdetected in vitro transcription and protein ApxIV exist, but not specifically for theexpression of ApxIV further understanding. To confirm this conclusion, we used A.pleuropneumoniae serotype1,8and15were cultured in vitro, using reversetranscription PCR, quantitative PCR, SDS-PAGE, Western Blot and MALDI massspectrometry and other methods, from transcription, protein level and theantigen-antibody reaction proved that the ApxIV expression under in vitro cultureconditions. A. pleuropneumoniae in vitro expression under different conditions isquite different, with the culture medium and the calcium ion concentration. Under theconditions of PPLO broth contains L-cysteine hydrochloride, L-cysteinehydrochloride, glucose, Tween-80,5mM calcium, it can be detected the highestApxIV protein bands. Different concentrations of calcium ions on ApxIV protein leveldetection have an important influence, but weaker effect on the transcriptional level. Therefore, we speculate that calcium may be an important regulatory factor ApxIVposttranslational modification.
In this study, cloning and expression of the six common antigen proteins betweenA. pleuropneumoniae and P. acnes and screen out two small peptides fragment of aprotein is a potential vaccine candidate, from the preliminary interpretation of theprotein levels of heterologous P, acnes immune protection Actinobacilluspleuropneumoniae infection mechanism. For the first time verified for the newluciferase Nanoluc expression and work effectively in A. pleuropneumoniae, prove itcan be a regulation studies tool and provides a new and convenient research method.From multiple angles proved A. pleuropneumoniae important virulence factor ApxIVexpression in vitro, initially discussed its expression regulation mechanism for thefurther study of this virulence factor and some help on A. pleuropneumoniaepathogenicity study and vaccine development.
引文
[1]布坎南, R.E.,伯杰细菌鉴定手册1984:科学出版社.897.
[2]白洁，顾威，王真子，随静,等,痤疮皮损内菌群的分离与研究[J].中国微生态学杂志,2005.17(6).
[3]MCDOWELL, A., A.L. PERRY, P.A. LAMBERT, et al., Anew phylogenetic groupof Propionibacterium acnes [J]. J Med Microbiol,2008.57:218-24.
[4]HALL, G.S., K. PRATT-RIPPIN, D.M. MEISLER, et al., Growth curve forPropionibacterium acnes [J]. Curr Eye Res,1994.13:465-6.
[5]姜春明，葛蒙梁,痤疮的发病机制研究进展[J].皮肤病与性病,2003.25:16-18.
[6]崔秀珍,傅志强,曲云英, MEBO抗菌作用实验研究[J].中国烧伤创伤杂志,1998.4:15-17.
[7]JAPPE, U., Pathological mechanisms of acne with special emphasis onPropionibacterium acnes and related therapy [J]. Acta Derm Venereol,2003.83:241-8.
[8]王大光，朱文元,痤疮发病机制中炎症的研究进展[J].中国美容医学,2004.13:3.
[9]STEINER, B., S. ROMERO-STEINER, D. CRUCE, et al., Cloning andsequencing of the hyaluronate lyase gene from Propionibacterium acnes [J]. Can JMicrobiol,1997.43:315-21.
[10]高天文,痤疮丙酸杆菌相关疾病[J].中国美容医学,2005.14(4).
[11]ALDAVE, A.J., J.D. STEIN, V.A. DERAMO, et al., Treatment strategies forpostoperative Propionibacterium acnes endophthalmitis [J]. Ophthalmology,1999.106:2395-401.
[12]HARRIS, A.E., C. HENNICKE, K. BYERS, et al., Postoperative discitis due toPropionibacterium acnes: a case report and review of the literature [J]. Surg Neurol,2005.63:538-41; discussion541.
[13]TUNNEY, M.M., PATRICK, S., CURRAN, M.D., RAMAGE, G., HANNA,D.,NIXON, J.R., GORMAN, S.P., DAVIS, R.I. ET AL, Detection of prosthetic hipinfection at revision arthroplasty by immunofluorescence microscopy and PCRamplification of the bacterial16S rRNA gene [J]. J Clin Microbiol,1999.37:3281–3290.
[14]ABOLNIK, I.Z., J.V. EATON, and D.J. SEXTON, Propionibacterium acnesvertebral osteomyelitis following lumbar puncture: case report and review [J]. ClinInfect Dis,1995.21:694-5.
[15]ZARATE, M.S., D. YAHNI, M. GUEVARA, et al.,[Post-surgery cerebral abscessdue to Propionibacterium acnes.][J]. Medicina (BAires),2009.69:170-2.
[16]朱莲花,痤疮丙酸杆菌在痤疮发病中的作用[J].中国美容医学,2006.15:476-477.
[17]COGEN, A.L., V. NIZET, and R.L. GALLO, Skin microbiota: a source of diseaseor defence?[J]. Br J Dermatol,2008.158:442-55.
[18]MIESCHER, S., M.P. STIERLI, M. TEUBER, et al., Propionicin SM1, abacteriocin from Propionibacterium jensenii DF1: isolation and characterization of theprotein and its gene [J]. SystAppl Microbiol,2000.23:174-84.
[19]FAYE, T., T. LANGSRUD, I.F. NES, et al., Biochemical and geneticcharacterization of propionicin T1, a new bacteriocin from Propionibacterium thoenii[J].Appl Environ Microbiol,2000.66:4230-6.
[20]FUJIMURA, S. and T. NAKAMURA, Purification and properties of abacteriocin-like substance (acnecin) of oral Propionibacterium acnes [J]. AntimicrobAgents Chemother,1978.14:893-8.
[21]ADLAM, C., E.S. BROUGHTON, and M.T. SCOTT, Enhanced resistance ofmice to infection with bacteria following pre-treatment with Corynebacterium parvum[J]. Nat New Biol,1972.235:219-20.
[22]SLJIVIC, V.S. and S.R. WATSON, The adjuvant effect of Corynebacteriumparvum: T-cell dependence of macrophage activation [J]. J Exp Med,1977.145:45-57.
[23]OKAMURA, H., M. WADA, K. NAGATA, et al., Induction of murine gammainterferon production by lipopolysaccharide and interleukin-2in Propionibacteriumacnes-induced peritoneal exudate cells [J]. Infect Immun,1987.55:335-41.
[24]OKAMURA H, N.K., KOMATSU T, TANIMOTO T, NUKATA Y, TANABE F,AKITA K, TORIGOE K, OKURA T, FUKUDA S,, A novel costimulatory factor forgamma interferon induction found in the livers of mice causes endotoxic shock [J].Infect Immun,1995.63:3966-3972.
[25]SCHORLEMMER, H.U., D. BITTER-SUERMANN, and A.C. ALLISON,Complement activation by the alternative pathway and macrophage enzyme secretionin the pathogenesis of chronic inflammation [J]. Immunology,1977.32:929-40.
[26]王世若,王兴龙,韩文瑜,现代动物免疫学2001:吉林科学技术出版社.393.
[27]ROSSI, G.A., R. FELLETTI, B. BALBI, et al., Symptomatic treatment ofrecurrent malignant pleural effusions with intrapleurally administeredCorynebacterium parvum. Clinical response is not associated with evidence ofenhancement of local cellular-mediated immunity [J]. Am Rev Respir Dis,1987.135:885-90.
[28]TAKEDA, K., T. KAISHO, and S. AKIRA, Toll-like receptors [J]. Annu RevImmunol,2003.21:335-76.
[29]AKIRA, S. and K. TAKEDA, Toll-like receptor signalling [J]. Nat Rev Immunol,2004.4:499-511.
[30]IWASAKI, A. and R. MEDZHITOV, Toll-like receptor control of the adaptiveimmune responses [J]. Nat Immunol,2004.5:987-95.
[31]VAN DUIN, D., R. MEDZHITOV, and A.C. SHAW, Triggering TLR signaling invaccination [J]. Trends Immunol,2006.27:49-55.
[32]KAISHO, T. and S. AKIRA, Toll-like receptors as adjuvant receptors [J]. BiochimBiophys Acta,2002.1589:1-13.
[33]JUGEAU, S., I. TENAUD, A.C. KNOL, et al., Induction of toll-like receptors byPropionibacterium acnes [J]. Br J Dermatol,2005.153:1105-13.
[34]TSUJI, S., M. MATSUMOTO, O. TAKEUCHI, et al., Maturation of humandendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin:involvement of toll-like receptors [J]. Infect Immun,2000.68:6883-90.
[35]KALIS, C., M. GUMENSCHEIMER, N. FREUDENBERG, et al., Requirementfor TLR9in the immunomodulatory activity of Propionibacterium acnes [J]. JImmunol,2005.174:4295-300.
[36]孙彬裕,高尚先,短小棒状杆菌CpG-DNA提取方法的研究[J].药物分析杂志,2009.29:4.
[37]IVAN M. ROITT, P.J.D., Roitt's Essential Immunology.10ed2001: BlackwellPublishing Ltd.481.
[38]MEGID, J., M.T. PERACOLLI, P.R. CURI, et al., Effect of vaccination and theimmunomodulators "bacillus of Calmette-Guerin, avridine and Propionibacteriumacnes" on rabies in mice [J]. Comp Immunol Microbiol Infect Dis,1998.21:305-18.
[39]MEGID, J. and R. KANENO, Natural killer activity in mice infected with rabiesvirus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator [J].Comp Immunol Microbiol Infect Dis,2000.23:91-7.
[40]MEGID, J., D.N. CREMONINI, and H. LEOMIL, Distribution of rabies virus ininfected mice, vaccinated and submitted to P. acnes as immunomodulator [J]. CompImmunol Microbiol Infect Dis,2002.25:237-48.
[41]MEGID, J., R. KANENO, C.N. NOZAKI, et al., Increased interleukin-10associated with low IL-6concentration correlated with greater survival rates in miceinfected by rabies virus vaccinated against it and immunomodulated with P. acnes [J].Comp Immunol Microbiol Infect Dis,2004.27:393-411.
[42]ROSSOL, S., R. VOTH, S. BRUNNER, et al., Corynebacterium parvum(Propionibacterium acnes): an inducer of tumor necrosis factor-alpha in humanperipheral blood mononuclear cells and monocytes in vitro [J]. Eur J Immunol,1990.20:1761-5.
[43]JUNG, Y.S., S.E. MATSUMOTO, M. YAMASHITA, et al., Propionibacteriumacnes acts as an adjuvant in in vitro immunization of human peripheral bloodmononuclear cells [J]. Biosci Biotechnol Biochem,2007.71:1963-9.
[44]MUSSALEM, J.S., J.R.C. VASCONCELOS, C.C. SQUAIELLA, et al., Adjuvanteffect of the propionibacterium acnes and its purified soluble polysaccharide on theimmunization with plasmidial DNA containing a Trypanosoma cruzi gene [J].Microbiology and Immunology,2006.50:253-263.
[45]SQUAIELLA, C.C., A.L. LONGHINI, E.G. BRAGA, et al., Modulation of thetype I hypersensitivity late phase reaction to OVA by Propionibacterium acnes-solublepolysaccharide [J]. Immunol Lett,2008.
[46]杨琳,白春杰,崔岩,短棒状菌菌体细胞与细胞代谢产物生物学活性的比较[J].药物生物技术,2005.12:3.
[47]DAWES, J., S.J. TUACH, and W.H. MCBRIDE, Properties of an antigenicpolysaccharide from Corynebacterium parvum [J]. J Bacteriol,1974.120:24-30.
[48]CANTRELL, J.L. and R.W. WHEAT, Antitumor activity and lymphoreticularstimulation properties of fractions isolated from Corynebacterium parvum [J]. CancerRes,1979.39:3554-63.
[49]JULAK, J., M. BEDNAR, F. TURECEK, et al., Fatty acid composition of aPropionibacterium acnes vaccine and its relationship to immunostimulatory activity[J]. Zentralbl Bakteriol Mikrobiol Hyg [A],1984.258:296-309.
[50]MARA, M., J. JULAK, M. BEDNAR, et al., The influence of Propionibacteriumacnes (Corynebacterium parvum) fractions on immune response in vivo [J]. ZentralblBakteriol,1994.281:549-55.
[51]虢国泰,刘宝昌,路松毅,短小棒菌细胞壁对小鼠粒系造血祖细胞的增殖作用[J].中国现代实用医学杂志,2005.4:2.
[52]王宇宏,高航,倪维华,等,短棒状杆菌有效成分的分离及其作用[J].中国生物制品学杂志,2005.18:2.
[53]安鸿志and袁现明,新编抗肿瘤药物手册2003:河南科学技术出版社.284.
[54]BAST, R.C., JR., J.S. BEREK, R. OBRIST, et al., Intraperitoneal immunotherapyof human ovarian carcinoma with Corynebacterium parvum [J]. Cancer Res,1983.43:1395-401.
[55]WOODRUFF, M. and P. WALBAUM, A phase-II trial of Corynebacteriumparvum as adjuvant to surgery in the treatment of operable lung cancer [J]. CancerImmunol Immunother,1983.16:114-6.
[56]LA COUR PETERSEN, E., P. HOKLAND, and J. ELLEGAARD, Adjuvantimmune stimulation with Corynebacterium parvum during maintenancechemotherapy of acute myeloid leukemia. Aprospective randomized study [J]. CancerImmunol Immunother,1983.16:88-92.
[57]LISSONI, P., S. BARNI, A. ARDIZZOIA, et al., Intracavitary administration ofinterleukin-2as palliative therapy for neoplastic effusions [J]. Tumori,1992.78:118-20.
[58]TIZARD.I, Round-Table Discussion Eqstim Immunostimulant, in37AnnualAAEP Meeting1992, J Equine Vet Sci.209-14.
[59]王海华,盛银平,曹义虎,等,鱼用免疫增强剂的作用机制及其应用研究进展[J].兽药与饲料添加剂,2005.10:3.
[60]FLAMINIO, M.J., B.R. RUSH, and W. SHUMAN, Immunologic function inhorses after non-specific immunostimulant administration [J]. Vet ImmunolImmunopathol,1998.63:303-15.
[61]DAVIS, E.G., B.R. RUSH, and F. BLECHA, Increases in cytokine andantimicrobial peptide gene expression in horses by immunomodulation withPropionibacterium acnes [J]. Vet Ther,2003.4:5-11.
[62]ISEKI, H., N. TAKABATAKE, N. OTA, et al., Babesia: the protective effects ofkilled Propionibacterium acnes on the infections of two rodent Babesia parasites inmice [J]. Exp Parasitol,2008.118:543-8.
[63]HOGAN, J.S., K.L. SMITH, D.A. TODHUNTER, et al., Efficacy of dry cowtherapy and a Propionibacterium acnes product in herds with low somatic cell count[J]. J Dairy Sci,1994.77:3331-7.
[64]HOGAN, J.S., K.L. SMITH, D.A. TODHUNTER, et al., Therapy ofexperimentally induced coliform mastitis with a Propionibacterium acnes product [J].J Dairy Sci,1994.77:462-7.
[65]DINSMORE, R.P., M.B. CATTELL, R.D. STEVENS, et al., Efficacy of aPropionibacterium acnes immunostimulant for treatment of chronic Staphylococcusaureus mastitis [J]. J Dairy Sci,1995.78:1932-6.
[66]周晨阳，刘海燕，杨发龙,新型免疫佐剂研究进展[J].现代畜牧兽医,2007:76-78.
[67]高尚先,宋静,刘星霞,等,无细胞短棒状杆菌纳米级制剂抗肿瘤作用及机理[J].中国肿瘤生物治疗杂志,2003.10:4.
[68]GAO, S., C. LIU, S. QU, et al., Non-cell Corynebacterium parvum generated bynanotechnology: a promising immunomodulator with less side effects [J]. IntImmunopharmacol,2007.7:1334-42.
[69]高尚先,李守悌,一种短棒状杆菌制剂或无细胞短棒状杆菌制剂在制备治疗HIV感染或爱滋病药剂中的应用, in中国药品生物制品检定所,知识产权出版社,Editor2005,北京元中知识产权代理有限责任公司:中国.18.
[70]PATTISON, I.H., D.G. HOWELL, and J. ELLIOT, A Haemophilus-like organismisolated from pig lung and the associated pneumonic lesions [J]. J Comp Pathol,1957.67:320-30.
[71]DOM, P. and F. HAESEBROUCK, Comparative virulence of NAD-dependentand NAD-independent Actinobacillus pleuropneumoniae strains [J]. ZentralblVeterinarmed B,1992.39:303-6.
[72]雷连成,韩文瑜,孙长江,等,胸膜肺炎放线杆菌血清型特异的疫苗候选基因的筛选及痤疮丙酸杆菌异源免疫[J].中国生物制品学杂志,2008.21:5.
[73]LEI, L., C. SUN, S. LU, et al., Selection of serotype-specific vaccine candidategenes in Actinobacillus pleuropneumoniae and heterologous immunization withPropionibacterium acnes [J]. Vaccine,2008.26:6274-80.
[74]BRUGGEMANN, H., A. HENNE, F. HOSTER, et al., The complete genomesequence of Propionibacterium acnes, a commensal of human skin [J]. Science,2004.305:671-3.
[75]谢芳,胸膜肺炎放线杆菌1型3型差异基因及两种蛋白功能研究,2010,吉林大学.158.
[76]王天奇,董发明,龙塔,洛阳地区规模化猪场传染性胸膜肺炎的血清学调查[J].中国兽医杂志,2006.42:28-29.
[77]樊祜卿,储岳峰,贺英,等,四川省部分地区猪传染性胸膜肺炎的流行病学调查[J].中国动物检疫,2009.26:49-50.
[78]BISGAARD, M., Ecology and significance of Pasteurellaceae in animals [J].Zentralbl Bakteriol,1993.279:7-26.
[79]NEGRETE-ABASCAL, E., M.E. REYES, R.M. GARCIA, et al., Flagella andMotility inActinobacillus pleuropneumoniae [J]. J Bacteriol,2003.185:664-8.
[80]蔡宝祥,猪传染性胸膜肺炎的诊断与防治[J].辽宁畜牧兽医,1996:41-42.
[81]NIELSEN, R., L.O. ANDRESEN, T. PLAMBECK, et al., Serologicalcharacterization of Actinobacillus pleuropneumoniae biotype2strains isolated frompigs in two Danish herds [J]. Vet Microbiol,1997.54:35-46.
[82]PERRY, M.B., Structural analysis of the lipopolysaccharide of Actinobacillus(Haemophilus) pleuropneumoniae serotype10[J]. Biochem Cell Biol,1990.68:808-10.
[83]KOMAL, J.P. and K.R. MITTAL, Grouping of Actinobacillus pleuropneumoniaestrains of serotypes1through12on the basis of their virulence in mice [J]. VetMicrobiol,1990.25:229-40.
[84]JACOBSEN, M.J., J.P. NIELSEN, and R. NIELSEN, Comparison of virulence ofdifferent Actinobacillus pleuropneumoniae serotypes and biotypes using an aerosolinfection model [J]. Vet Microbiol,1996.49:159-68.
[85]CRUIJSEN, T., L.A. VAN LEENGOED, M. HAM-HOFFIES, et al.,Convalescent pigs are protected completely against infection with a homologousActinobacillus pleuropneumoniae strain but incompletely against aheterologous-serotype strain [J]. Infect Immun,1995.63:2341-3.
[86]TADJINE, M. and K.R. MITTAL, Study of antigenic heterogeneity amongActinobacillus pleuropneumoniae serotype7strains [J]. Vet Microbiol,2001.78:49-60.
[87]GAGNE, A., S. LACOUTURE, A. BROES, et al., Development of animmunomagnetic method for selective isolation of Actinobacillus pleuropneumoniaeserotype1from tonsils [J]. J Clin Microbiol,1998.36:251-4.
[88]ANGEN, O., P.M. HEEGAARD, D.T. LAVRITSEN, et al., Isolation ofActinobacillus pleuropneumoniae serotype2by immunomagnetic separation [J]. VetMicrobiol,2001.79:19-29.
[89]MITTAL, K.R., R. HIGGINS, and S. LARIVIERE, Determination of antigenicspecificity and relationship among Haemophilus pleuropneumoniae serotypes by anindirect hemagglutination test [J]. J Clin Microbiol,1983.17:787-90.
[90]MITTAL, K.R., Cross-reactions between Actinobacillus (Haemophilus)pleuropneumoniae strains of serotypes1and9[J]. J Clin Microbiol,1990.28:535-9.
[91]MITTAL, K.R., R. HIGGINS, and S. LARIVIERE, Serological studies ofActinobacillus (Haemophilus) pleuropneumoniae strains of serotype6and theirantigenic relationship with other serotypes [J]. Vet Rec,1988.122:199-203.
[92]INZANA, T.J., J. TODD, C. KOCH, et al., Serotype specificity of immunologicalassays for the capsular polymer of Actinobacillus pleuropneumoniae serotypes1and9[J]. Vet Microbiol,1992.31:351-62.
[93]MITTAL, K.R. and S. BOURDON, Cross-reactivity and antigenic heterogeneityamong Actinobacillus pleuropneumoniae strains of serotypes4and7[J]. J ClinMicrobiol,1991.29:1344-7.
[94]NICOLET, J., P. PAROZ, M. KRAWINKLER, et al., An enzyme-linkedimmunosorbent assay, using an EDTA-extracted antigen for the serology ofHaemophilus pleuropneumoniae [J].Am J Vet Res,1981.42:2139-42.
[95]TROTTIER, Y.L., P.F. WRIGHT, and S. LARIVIERE, Optimization andstandardization of an enzyme-linked immunosorbent assay protocol for serodiagnosisofActinobacillus pleuropneumoniae serotype5[J]. J Clin Microbiol,1992.30:46-53.
[96]FREY, J., M. BECK, J.F. VAN DEN BOSCH, et al., Development of an efficientPCR method for toxin typing of Actinobacillus pleuropneumoniae strains [J]. MolCell Probes,1995.9:277-82.
[97]GRAM, T. and P. AHRENS, Improved diagnostic PCR assay for Actinobacilluspleuropneumoniae based on the nucleotide sequence of an outer membranelipoprotein [J]. J Clin Microbiol,1998.36:443-8.
[98]SCHALLER, A., S.P. DJORDJEVIC, G.J. EAMENS, et al., Identification anddetection of Actinobacillus pleuropneumoniae by PCR based on the gene apxIVA [J].Vet Microbiol,2001.79:47-62.
[99]YANG, W., C. PIN, G. HAIBING, et al., Loop-mediated isothermal amplificationtargeting the apxIVA gene for detection of Actinobacillus pleuropneumoniae [J].FEMS Microbiol Lett,2009.300:83-9.
[100]DE LA PUENTE-REDONDO, V.A., N.G. DEL BLANCO, C.B.GUTIERREZ-MARTIN, et al., Detection and subtyping of Actinobacilluspleuropneumoniae strains by PCR-RFLP analysis of the tbpA and tbpB genes [J]. ResMicrobiol,2000.151:669-81.
[101]GRAM, T., P. AHRENS, M. ANDREASEN, et al., An Actinobacilluspleuropneumoniae PCR typing system based on the apx and omlA genes--evaluationof isolates from lungs and tonsils of pigs [J]. Vet Microbiol,2000.75:43-57.
[102]JESSING, S.G., O. ANGEN, and T.J. INZANA, Evaluation of a multiplex PCRtest for simultaneous identification and serotyping of Actinobacilluspleuropneumoniae serotypes2,5, and6[J]. J Clin Microbiol,2003.41:4095-100.
[103]SCHUCHERT, J.A., T.J. INZANA, O. ANGEN, et al., Detection andidentification of Actinobacillus pleuropneumoniae serotypes1,2, and8by multiplexPCR [J]. J Clin Microbiol,2004.42:4344-8.
[104]ANGEN, O., P. AHRENS, and S.G. JESSING, Development of a multiplex PCRtest for identification of Actinobacillus pleuropneumoniae serovars1,7, and12[J].Vet Microbiol,2008.132:312-8.
[105]ZHOU, L., S.C. JONES, O. ANGEN, et al., Multiplex PCR that can distinguishbetween immunologically cross-reactive serovar3,6, and8Actinobacilluspleuropneumoniae strains [J]. J Clin Microbiol,2008.46:800-3.
[106]ITO, H., Development of a cps-based multiplex PCR for typing of actinobacilluspleuropneumoniae serotypes1,2and5[J]. J Vet Med Sci,2010.72:653-5.
[107]XIAO, G., S. CAO, X. HUANG, et al., DNA microarray-based identification andtyping ofActinobacillus pleuropneumoniae [J]. Can J Vet Res,2009.73:190-9.
[108]TAYLOR, D., B. STRAW, S. D'ALLAIRE, et al., Diseases of Swine.8ed, ed.Ames1999: Iowa State University Press.
[109]MOLLER, K., L.V. ANDERSEN, G. CHRISTENSEN, et al., Optimalization ofthe detection of NAD dependent Pasteurellaceae from the respiratory tract ofslaughterhouse pigs [J]. Vet Microbiol,1993.36:261-71.
[110]SIDIBE, M., S. MESSIER, S. LARIVIERE, et al., Detection of Actinobacilluspleuropneumoniae in the porcine upper respiratory tract as a complement toserological tests [J]. Can J Vet Res,1993.57:204-8.
[111]DUBREUIL, J.D., M. JACQUES, K.R. MITTAL, et al., Actinobacilluspleuropneumoniae surface polysaccharides: their role in diagnosis andimmunogenicity [J].Anim Health Res Rev,2000.1:73-93.
[112]BLACKALL, P.J., H.L. KLAASEN, H. VAN DEN BOSCH, et al., Proposal of anew serovar of Actinobacillus pleuropneumoniae: serovar15[J]. Vet Microbiol,2002.84:47-52.
[113]FREY, J., Virulence in Actinobacillus pleuropneumoniae and RTX toxins [J].Trends Microbiol,1995.3:257-61.
[114]JACQUES, M., Role of lipo-oligosaccharides and lipopolysaccharides inbacterial adherence [J]. Trends Microbiol,1996.4:408-9.
[115]RAMJEET, M., V. DESLANDES, F. ST MICHAEL, et al., Truncation of thelipopolysaccharide outer core affects susceptibility to antimicrobial peptides andvirulence of Actinobacillus pleuropneumoniae serotype1[J]. J Biol Chem,2005.280:39104-14.
[116]HAESEBROUCK, F., K. CHIERS, I. VAN OVERBEKE, et al., Actinobacilluspleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis andprotection [J]. Vet Microbiol,1997.58:239-49.
[117]JACQUES, M., Surface polysaccharides and iron-uptake systems ofActinobacillus pleuropneumoniae [J]. Can J Vet Res,2004.68:81-5.
[118]BACKSTROM, L., Present uses of and experiences with swine vaccines [J].Adv Vet Med,1999.41:419-28.
[119]HAESEBROUCK, F., F. PASMANS, K. CHIERS, et al., Efficacy of vaccinesagainst bacterial diseases in swine: what can we expect?[J]. Vet Microbiol,2004.100:255-68.
[120]VAN OVERBEKE, I., K. CHIERS, E. DONNE, et al., Effect of endobronchialchallenge with Actinobacillus pleuropneumoniae serotype10of pigs vaccinated withbacterins consisting of A. pleuropneumoniae serotype10grown under NAD-rich andNAD-restricted conditions [J]. J Vet Med B Infect Dis Vet Public Health,2003.50:289-93.
[121]JOLIE, R.A., M.H. MULKS, and B.J. THACKER, Cross-protection experimentsin pigs vaccinated with Actinobacillus pleuropneumoniae subtypes1A and1B [J]. VetMicrobiol,1995.45:383-91.
[122]FURESZ, S.E., B.A. MALLARD, J.T. BOSSE, et al., Antibody-andcell-mediated immune responses of Actinobacillus pleuropneumoniae-infected andbacterin-vaccinated pigs [J]. Infect Immun,1997.65:358-65.
[123]HAGA, Y., S. OGINO, S. OHASHI, et al., Protective efficacy of anaffinity-purified hemolysin vaccine against experimental swine pleuropneumonia [J].J Vet Med Sci,1997.59:115-20.
[124]SEAH, J.N., J. FREY, and J. KWANG, The N-terminal domain of RTX toxinApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice [J].Infect Immun,2002.70:6464-7.
[125]HIGGINS, R., S. LARIVIERE, K.R. MITTAL, et al., Evaluation of a KilledVaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae [J].Can Vet J,1985.26:86-89.
[126]THACKER, B. and M. MULKS, Evaluation of commercial Haemophiluspleuropneumoniae vaccine, in Proceedings of International Pig Veterinary SocietyCongress1988.87.
[127]FENWICK, B. and S. HENRY, Porcine pleuropneumonia [J]. J Am Vet MedAssoc,1994.204:1334-40.
[128]APPLEYARD, G.D., S.E. FURESZ, and B.N. WILKIE, Blood lymphocytesubsets in pigs vaccinated and challenged with Actinobacillus pleuropneumoniae [J].Vet Immunol Immunopathol,2002.86:221-8.
[129]WITTE, A., G. WANNER, U. BLASI, et al., Endogenous transmembrane tunnelformation mediated by phi X174lysis protein E [J]. J Bacteriol,1990.172:4109-14.
[130]WITTE, A., G. WANNER, M. SULZNER, et al., Dynamics of PhiX174proteinE-mediated lysis of Escherichia coli [J].Arch Microbiol,1992.157:381-8.
[131]FELNEROVA, D., P. KUDELA, J. BIZIK, et al., T cell-specific immuneresponse induced by bacterial ghosts [J]. Med Sci Monit,2004.10: BR362-70.
[132]SZOSTAK, M.P., A. HENSEL, F.O. EKO, et al., Bacterial ghosts: non-livingcandidate vaccines [J]. J Biotechnol,1996.44:161-70.
[133]LUBITZ, W., A. WITTE, F.O. EKO, et al., Extended recombinant bacterialghost system [J]. J Biotechnol,1999.73:261-73.
[134]LUBITZ, W., Bacterial ghosts as carrier and targeting systems [J]. Expert OpinBiol Ther,2001.1:765-71.
[135]JALAVA, K., F.O. EKO, E. RIEDMANN, et al., Bacterial ghosts as carrier andtargeting systems for mucosal antigen delivery [J]. Expert Rev Vaccines,2003.2:45-51.
[136]RIEDMANN, E.M., J.M. KYD, A.W. CRIPPS, et al., Bacterial ghosts asadjuvant particles [J]. Expert Rev Vaccines,2007.6:241-53.
[137]KATINGER, A., W. LUBITZ, M.P. SZOSTAK, et al., Pigs aerogenouslyimmunized with genetically inactivated (ghosts) or irradiated Actinobacilluspleuropneumoniae are protected against a homologous aerosol challenge despitediffering in pulmonary cellular and antibody responses [J]. J Biotechnol,1999.73:251-60.
[138]HENSEL, A., V. HUTER, A. KATINGER, et al., Intramuscular immunizationwith genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype9protects pigs against homologous aerosol challenge and prevents carrier state [J].Vaccine,2000.18:2945-55.
[139]HUTER, V., A. HENSEL, E. BRAND, et al., Improved protection against lungcolonization by Actinobacillus pleuropneumoniae ghosts: characterization of agenetically inactivated vaccine [J]. J Biotechnol,2000.83:161-72.
[140]NIELSEN, R., Haemophilus pleuropneumoniae serotypes--cross protectionexperiments [J]. Nord Vet Med,1984.36:221-34.
[141]GOETHE, R., O.F. GONZALES, T. LINDNER, et al., A novel strategy forprotective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction ofcultures induced by iron restriction [J]. Vaccine,2000.19:966-75.
[142]WILLSON, P.J., A. ROSSI-CAMPOS, and A.A. POTTER, Tissue reaction andimmunity in swine immunized with Actinobacillus pleuropneumoniae vaccines [J].Can J Vet Res,1995.59:299-305.
[143]RIOUX, S., D. DUBREUIL, C. BEGIN, et al., Evaluation of protective efficacyof an Actinobacillus pleuropneumoniae serotype1lipopolysaccharide-proteinconjugate in mice [J]. Comp Immunol Microbiol Infect Dis,1997.20:63-74.
[144]RIOUX, S., C. GIRARD, J.D. DUBREUIL, et al., Evaluation of the protectiveefficacy of Actinobacillus pleuropneumoniae serotype1detoxifiedlipopolysaccharides or O-polysaccharide-protein conjugate in pigs [J]. Res Vet Sci,1998.65:165-7.
[145]SAZE, K., C. KINOSHITA, F. SHIBA, et al., Effect of passive immunizationwith serotype-specific monoclonal antibodies on Actinobacillus pleuropneumoniaeinfection of mice [J]. J Vet Med Sci,1994.56:97-102.
[146]INZANA, T.J., J. MA, T. WORKMAN, et al., Virulence properties andprotective efficacy of the capsular polymer of Haemophilus (Actinobacillus)pleuropneumoniae serotype5[J]. Infect Immun,1988.56:1880-9.
[147]BYRD, W. and A.M. HOOKE, Immunization with temperature-sensitivemutants of Actinobacillus pleuropneumoniae induces protectivehemolysin-neutralizing antibodies in mice [J]. Curr Microbiol,1997.34:149-54.
[148]RAPP, V.J., R.S. MUNSON, JR., and R.F. ROSS, Outer membrane proteinprofiles of Haemophilus pleuropneumoniae [J]. Infect Immun,1986.52:414-20.
[149]GONZALEZ, G.C., D.L. CAAMANO, and A.B. SCHRYVERS, Identificationand characterization of a porcine-specific transferrin receptor in Actinobacilluspleuropneumoniae [J]. Mol Microbiol,1990.4:1173-9.
[150]GERLACH, G.F., S. KLASHINSKY, C. ANDERSON, et al., Characterization oftwo genes encoding distinct transferrin-binding proteins in different Actinobacilluspleuropneumoniae isolates [J]. Infect Immun,1992.60:3253-61.
[151]DENEER, H.G. and A.A. POTTER, Identification of a maltose-inducible majorouter membrane protein in Actinobacillus (Haemophilus) pleuropneumoniae [J].Microb Pathog,1989.6:425-32.
[152]FREY, J., P. KUHNERT, L. VILLIGER, et al., Cloning and characterization ofan Actinobacillus pleuropneumoniae outer membrane protein belonging to the familyof PALlipoproteins [J]. Res Microbiol,1996.147:351-61.
[153]GERLACH, G.F., C. ANDERSON, S. KLASHINSKY, et al., Molecularcharacterization of a protective outer membrane lipoprotein (OmlA) fromActinobacillus pleuropneumoniae serotype1[J]. Infect Immun,1993.61:565-72.
[154]HODGETTS, A., J.T. BOSSE, J.S. KROLL, et al., Analysis of differentialprotein expression in Actinobacillus pleuropneumoniae by Surface Enhanced LaserDesorption Ionisation--ProteinChip (SELDI) technology [J]. Vet Microbiol,2004.99:215-25.
[155]MAAS, A., J. MEENS, N. BALTES, et al., Development of a DIVA subunitvaccine against Actinobacillus pleuropneumoniae infection [J]. Vaccine,2006.24:7226-37.
[156]CRUZ, W.T., Y.A. NEDIALKOV, B.J. THACKER, et al., Molecularcharacterization of a common48-kilodalton outer membrane protein of Actinobacilluspleuropneumoniae [J]. Infect Immun,1996.64:83-90.
[157]VAN DEN BOSCH, H. and J. FREY, Interference of outer membrane proteinPalA with protective immunity against Actinobacillus pleuropneumoniae infections invaccinated pigs [J]. Vaccine,2003.21:3601-7.
[158]DESLANDES, V., J.H. NASH, J. HAREL, et al., Transcriptional profiling ofActinobacillus pleuropneumoniae under iron-restricted conditions [J]. BMCGenomics,2007.8:72.
[159]GERLACH, G.F., C. ANDERSON, A.A. POTTER, et al., Cloning andexpression of a transferrin-binding protein from Actinobacillus pleuropneumoniae [J].Infect Immun,1992.60:892-8.
[160]ROSSI-CAMPOS, A., C. ANDERSON, G.F. GERLACH, et al., Immunization ofpigs against Actinobacillus pleuropneumoniae with two recombinant proteinpreparations [J]. Vaccine,1992.10:512-8.
[161]VAN OVERBEKE, I., K. CHIERS, R. DUCATELLE, et al., Effect ofendobronchial challenge with Actinobacillus pleuropneumoniae serotype9of pigsvaccinated with a vaccine containing Apx toxins and transferrin-binding proteins [J]. JVet Med B Infect Dis Vet Public Health,2001.48:15-20.
[162]MIKAEL, L.G., R. SRIKUMAR, J.W. COULTON, et al., fhuAof Actinobacilluspleuropneumoniae encodes a ferrichrome receptor but is not regulated by iron [J].Infect Immun,2003.71:2911-5.
[163]MIKAEL, L.G., P.D. PAWELEK, J. LABRIE, et al., Molecular cloning andcharacterization of the ferric hydroxamate uptake (fhu) operon in Actinobacilluspleuropneumoniae [J]. Microbiology,2002.148:2869-82.
[164]SRIKUMAR, R., L.G. MIKAEL, P.D. PAWELEK, et al., Molecular cloning ofhaemoglobin-binding protein HgbA in the outer membrane of Actinobacilluspleuropneumoniae [J]. Microbiology,2004.150:1723-34.
[165]SHAKARJI, L., L.G. MIKAEL, R. SRIKUMAR, et al., Fhua and HgbA, outermembrane proteins of Actinobacillus pleuropneumoniae: their role as virulencedeterminants [J]. Can J Microbiol,2006.52:391-6.
[166]INZANA, T.J., Virulence properties of Actinobacillus pleuropneumoniae [J].Microb Pathog,1991.11:305-16.
[167]CRUIJSEN, T.L., L.A. VAN LEENGOED, T.C. DEKKER-NOOREN, et al.,Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolarmacrophages and polymorphonuclear leukocytes isolated from pigs [J]. Infect Immun,1992.60:4867-71.
[168]JANSEN, R., J. BRIAIRE, A.B. VAN GEEL, et al., Genetic map of theActinobacillus pleuropneumoniae RTX-toxin (Apx) operons: characterization of theApxIII operons [J]. Infect Immun,1994.62:4411-8.
[169]FURESZ, S.E., B.N. WILKIE, B.A. MALLARD, et al., Anti-haemolysin IgG1to IgG2ratios correlate with haemolysin neutralization titres and lung lesion scores inActinobacillus pleuropneumoniae infected pigs [J]. Vaccine,1998.16:1971-5.
[170]SEAH, J.N. and J. KWANG, Localization of linear cytotoxic and pro-apoptoticepitopes in RTX toxin ApxIII of Actinobacillus pleuropneumoniae [J]. Vaccine,2004.22:1494-7.
[171]BYRD, W. and S. KADIS, Preparation, characterization, and immunogenicity ofconjugate vaccines directed against Actinobacillus pleuropneumoniae virulencedeterminants [J]. Infect Immun,1992.60:3042-51.
[172]FREY, J., H. VAN DEN BOSCH, R. SEGERS, et al., Identification of a secondhemolysin (HlyII) in Actinobacillus pleuropneumoniae serotype1and expression ofthe gene in Escherichia coli [J]. Infect Immun,1992.60:1671-6.
[173]BEAUDET, R., G. MCSWEEN, G. BOULAY, et al., Protection of mice andswine against infection with Actinobacillus pleuropneumoniae by vaccination [J]. VetMicrobiol,1994.39:71-81.
[174]FREY, J., Exotoxins of Actinobacillus pleuropneumonia [J]. Haemophilus,Actinobacillus, and Pasteurella,1995.
[175]MADSEN, M.E., K.G. CARNAHAN, and R.N. THWAITS, Evaluation of piglungs following an experimental challenge with Actinobacillus pleuropneumoniaeserotype1and5in pigs inoculated with either hemolysin protein and/or outermembrane proteins [J]. FEMS Microbiol Lett,1995.131:329-35.
[176]CHIERS, K., I. VAN OVERBEKE, P. DE LAENDER, et al., Effects ofendobronchial challenge with Actinobacillus pleuropneumoniae serotype9of pigsvaccinated with inactivated vaccines containing the Apx toxins [J]. Vet Q,1998.20:65-9.
[177]TUMAMAO, J.Q., R.E. BOWLES, H. VAN DEN BOSCH, et al., Comparisonof the efficacy of a subunit and a live streptomycin-dependent porcinepleuropneumonia vaccine [J].Aust Vet J,2004.82:370-4.
[178]MEEUSEN, E.N., J. WALKER, A. PETERS, et al., Current status of veterinaryvaccines [J]. Clin Microbiol Rev,2007.20:489-510, table of contents.
[179]MOSIER, D., J. IANDOLO, D. ROGERS, et al., Characterization of a54-kDaheat-shock-inducible protein of Pasteurella haemolytica [J]. Vet Microbiol,1998.60:67-73.
[180]THOMAS, L.D., M.L. DUNKLEY, R. MOORE, et al., Catalase immunizationfrom Pseudomonas aeruginosa enhances bacterial clearance in the rat lung [J].Vaccine,2000.19:348-57.
[181]WILLSON, P.J., G.F. GERLACH, S. KLASHINSKY, et al., Cloning andcharacterization of the gene coding for NADPH-sulfite reductase hemoprotein fromActinobacillus pleuropneumoniae and use of the protein product as a vaccine [J]. CanJ Vet Res,2001.65:206-12.
[182]SCHALLER, A., R. KUHN, P. KUHNERT, et al., Characterization of apxIVA, anew RTX determinant of Actinobacillus pleuropneumoniae [J]. Microbiology,1999.145(Pt8):2105-16.
[183]HAESEBROUK, F., A. VAN DE KERKHOF, P. DOM, et al., Cross-protectionbetween Actinobacillus pleuropneumoniae biotypes-serotypes in pigs [J]. VetMicrobiol,1996.52:277-84.
[184]FULLER, T.E., B.J. THACKER, and M.H. MULKS, A riboflavin auxotroph ofActinobacillus pleuropneumoniae is attenuated in swine [J]. Infect Immun,1996.64:4659-64.
[185]INGHAM, A., Y. ZHANG, and C. PRIDEAUX, Attenuation of Actinobacilluspleuropneumoniae by inactivation of aroQ [J]. Vet Microbiol,2002.84:263-73.
[186]GARSIDE, L.H., M. COLLINS, P.R. LANGFORD, et al., Actinobacilluspleuropneumoniae serotype1carrying the defined aroA mutation is fully avirulent inthe pig [J]. Res Vet Sci,2002.72:163-7.
[187]BALTES, N., I. HENNIG-PAUKA, I. JACOBSEN, et al., Identification ofdimethyl sulfoxide reductase in Actinobacillus pleuropneumoniae and its role ininfection [J]. Infect Immun,2003.71:6784-92.
[188]SHEEHAN, B.J., P.R. LANGFORD, A.N. RYCROFT, et al.,
[Cu,Zn]-Superoxide dismutase mutants of the swine pathogen Actinobacilluspleuropneumoniae are unattenuated in infections of the natural host [J]. Infect Immun,2000.68:4778-81.
[189]BALTES, N., W. TONPITAK, G.F. GERLACH, et al., Actinobacilluspleuropneumoniae iron transport and urease activity: effects on bacterial virulenceand host immune response [J]. Infect Immun,2001.69:472-8.
[190]BOSSE, J.T., R.P. JOHNSON, M. NEMEC, et al., Protective local and systemicantibody responses of swine exposed to an aerosol of Actinobacilluspleuropneumoniae serotype1[J]. Infect Immun,1992.60:479-84.
[191]XU, F., X. CHEN, A. SHI, et al., Characterization and immunogenicity of anapxIA mutant of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2006.118:230-9.
[192]PRIDEAUX, C.T., L. PIERCE, J. KRYWULT, et al., Protection of mice againstchallenge with homologous and heterologous serovars of Actinobacilluspleuropneumoniae after live vaccination [J]. Curr Microbiol,1998.37:324-32.
[193]PRIDEAUX, C.T., C. LENGHAUS, J. KRYWULT, et al., Vaccination andprotection of pigs against pleuropneumonia with a vaccine strain of Actinobacilluspleuropneumoniae produced by site-specific mutagenesis of the ApxII operon [J].Infect Immun,1999.67:1962-6.
[194]INZANA, T.J., G. GLINDEMANN, B. FENWICK, et al., Risk assessment oftransmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae [J].Vet Microbiol,2004.104:63-71.
[195]BEI, W., Q. HE, R. ZHOU, et al., Evaluation of immunogenicity and protectiveefficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drugresistance marker in the pigs [J]. Vet Microbiol,2007.125:120-7.
[196]BEI, W., Q. HE, L. YAN, et al., Construction and characterization of a live,attenuated apxIICAinactivation mutant of Actinobacillus pleuropneumoniae lacking adrug resistance marker [J]. FEMS Microbiol Lett,2005.243:21-7.
[197]LIN, L., W. BEI, Y. SHA, et al., Construction and immunogencity of aDeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar1[J]. FEMS Microbiol Lett,2007.274:55-62.
[198]INZANA, T.J., J. TODD, and H.P. VEIT, Safety, stability, and efficacy ofnoncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines[J]. Infect Immun,1993.61:1682-6.
[199]TONPITAK, W., N. BALTES, I. HENNIG-PAUKA, et al., Construction of anActinobacillus pleuropneumoniae serotype2prototype live negative-marker vaccine[J]. Infect Immun,2002.70:7120-5.
[200]MAAS, A., I.D. JACOBSEN, J. MEENS, et al., Use of an Actinobacilluspleuropneumoniae multiple mutant as a vaccine that allows differentiation ofvaccinated and infected animals [J]. Infect Immun,2006.74:4124-32.
[201]BOSSE, J.T., H. JANSON, B.J. SHEEHAN, et al., Actinobacilluspleuropneumoniae: pathobiology and pathogenesis of infection [J]. Microbes Infect,2002.4:225-35.
[202]JACQUES, M., M. BELANGER, G. ROY, et al., Adherence of Actinobacilluspleuropneumoniae to porcine tracheal epithelial cells and frozen lung sections [J]. VetMicrobiol,1991.27:133-43.
[203]DOM, P., F. HAESEBROUCK, R. DUCATELLE, et al., In vivo association ofActinobacillus pleuropneumoniae serotype2with the respiratory epithelium of pigs[J]. Infect Immun,1994.62:1262-7.
[204]ABUL-MILH, M., S.E. PARADIS, J.D. DUBREUIL, et al., Binding ofActinobacillus pleuropneumoniae lipopolysaccharides to glycosphingolipidsevaluated by thin-layer chromatography [J]. Infect Immun,1999.67:4983-7.
[205]MORA, J.R., M.R. BONO, N. MANJUNATH, et al., Selective imprinting ofgut-homing T cells by Peyer's patch dendritic cells [J]. Nature,2003.424:88-93.
[206]KUNKEL, E.J. and E.C. BUTCHER, Plasma-cell homing [J]. Nat Rev Immunol,2003.3:822-9.
[207]PILETTE, C., Y. OUADRHIRI, V. GODDING, et al., Lung mucosal immunity:immunoglobulin-Arevisited [J]. Eur Respir J,2001.18:571-88.
[208]WOOF, J.M. and M.A. KERR, The function of immunoglobulin A in immunity[J]. J Pathol,2006.208:270-82.
[209]NEUTRA, M.R. and P.A. KOZLOWSKI, Mucosal vaccines: the promise and thechallenge [J]. Nat Rev Immunol,2006.6:148-58.
[210]GERDTS, V., G.K. MUTWIRI, S.K. TIKOO, et al., Mucosal delivery ofvaccines in domestic animals [J]. Vet Res,2006.37:487-510.
[211]PABST, R. and R.M. BINNS, The immune system of the respiratory tract in pigs[J]. Vet Immunol Immunopathol,1994.43:151-6.
[212]BOUVET, J.P., N. DECROIX, and P. PAMONSINLAPATHAM, Stimulation oflocal antibody production: parenteral or mucosal vaccination?[J]. Trends Immunol,2002.23:209-13.
[213]LIAO, C.W., I.C. CHENG, K.S. YEH, et al., Release characteristics ofmicrospheres prepared by co-spray drying Actinobacillus pleuropneumoniae antigensand aqueous ethyl-cellulose dispersion [J]. J Microencapsul,2001.18:285-97.
[214]RYAN, E.J., L.M. DALY, and K.H. MILLS, Immunomodulators and deliverysystems for vaccination by mucosal routes [J]. Trends Biotechnol,2001.19:293-304.
[215]SHIN, S.J., J.L. BAE, Y.W. CHO, et al., Induction of antigen-specific immuneresponses by oral vaccination with Saccharomyces cerevisiae expressingActinobacillus pleuropneumoniae ApxIIA [J]. FEMS Immunol Med Microbiol,2005.43:155-64.
[216]LEE, K.Y., D.H. KIM, T.J. KANG, et al., Induction of protective immuneresponses against the challenge of Actinobacillus pleuropneumoniae by the oraladministration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria[J]. FEMS Immunol Med Microbiol,2006.48:381-9.
[217]LIAO, C.W., H.Y. CHIOU, K.S. YEH, et al., Oral immunization usingformalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped inmicrospheres with aqueous dispersion polymers prepared using a co-spray dryingprocess [J]. Prev Vet Med,2003.61:1-15.
[218]SOSROSENO, W., A review of the mechanisms of oral tolerance andimmunotherapy [J]. J R Soc Med,1995.88:14-7.
[219]TAKAHASHI, I., M. MARINARO, H. KIYONO, et al., Mechanisms formucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin [J]. JInfect Dis,1996.173:627-35.
[220]RAPPUOLI, R., M. PIZZA, G. DOUCE, et al., Structure and mucosaladjuvanticity of cholera and Escherichia coli heat-labile enterotoxins [J]. ImmunolToday,1999.20:493-500.
[221]MCCLUSKIE, M.J. and H.L. DAVIS, CpG DNA as mucosal adjuvant [J].Vaccine,1999.18:231-7.
[222]KRIEG, A.M., Immune effects and mechanisms of action of CpG motifs [J].Vaccine,2000.19:618-22.
[223]RANKIN, R., R. PONTAROLLO, X. IOANNOU, et al., CpG motifidentification for veterinary and laboratory species demonstrates that sequencerecognition is highly conserved [J]. Antisense Nucleic Acid Drug Dev,2001.11:333-40.
[224]ALCON, V., M. BACA-ESTRADA, M. VEGA-LOPEZ, et al., Mucosal deliveryof bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles inpigs [J].AAPS J,2005.7: E566-71.
[225]ALCON, V.L., M. FOLDVARI, M. SNIDER, et al., Induction of protectiveimmunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in alipid-based delivery system (Biphasix)[J]. Vaccine,2003.21:1811-4.
[226]KIM, T.J., K.H. KIM, and J.I. LEE, Stimulation of mucosal and systemicantibody responses against recombinant transferrin-binding protein B ofActinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets[J]. J Vet Med Sci,2007.69:535-9.
[227]SLAUCH, J.M., M.J. MAHAN, and J.J. MEKALANOS, In vivo expressiontechnology for selection of bacterial genes specifically induced in host tissues [J].Methods Enzymol,1994.235:481-92.
[228]FULLER, T.E., R.J. SHEA, B.J. THACKER, et al., Identification of in vivoinduced genes in Actinobacillus pleuropneumoniae [J]. Microb Pathog,1999.27:311-27.
[229]SHEA, R.J. and M.H. MULKS, ohr, Encoding an organic hydroperoxidereductase, is an in vivo-induced gene in Actinobacillus pleuropneumoniae [J]. InfectImmun,2002.70:794-802.
[230]WANG, J., A. MUSHEGIAN, S. LORY, et al., Large-scale isolation of candidatevirulence genes of Pseudomonas aeruginosa by in vivo selection [J]. Proc Natl AcadSci U SA,1996.93:10434-9.
[231]FULLER, T.E., M.J. KENNEDY, and D.E. LOWERY, Identification ofPasteurella multocida virulence genes in a septicemic mouse model usingsignature-tagged mutagenesis [J]. Microb Pathog,2000.29:25-38.
[232]WAGNER, T.K. and M.H. MULKS, A subset of Actinobacilluspleuropneumoniae in vivo induced promoters respond to branched-chain amino acidlimitation [J]. FEMS Immunol Med Microbiol,2006.48:192-204.
[233]WAGNER, T.K. and M.H. MULKS, Identification of the Actinobacilluspleuropneumoniae leucine-responsive regulatory protein and its involvement in theregulation of in vivo-induced genes [J]. Infect Immun,2007.75:91-103.
[234]FULLER, T.E., B.J. THACKER, C.O. DURAN, et al., A genetically-definedriboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine[J]. Vaccine,2000.18:2867-77.
[235]FULLER, T.E., S. MARTIN, J.F. TEEL, et al., Identification of Actinobacilluspleuropneumoniae virulence genes using signature-tagged mutagenesis in a swineinfection model [J]. Microb Pathog,2000.29:39-51.
[236]SHEEHAN, B.J., J.T. BOSSE, A.J. BEDDEK, et al., Identification ofActinobacillus pleuropneumoniae genes important for survival during infection in itsnatural host [J]. Infect Immun,2003.71:3960-70.
[237]MARONCLE, N., D. BALESTRINO, C. RICH, et al., Identification ofKlebsiella pneumoniae genes involved in intestinal colonization and adhesion usingsignature-tagged mutagenesis [J]. Infect Immun,2002.70:4729-34.
[238]BEDDEK, A.J., B.J. SHEEHAN, J.T. BOSSE, et al., Two TonB systems inActinobacillus pleuropneumoniae: their roles in iron acquisition and virulence [J].Infect Immun,2004.72:701-8.
[239]TONPITAK, W., S. THIEDE, W. OSWALD, et al., Actinobacilluspleuropneumoniae iron transport: a set of exbBD genes is transcriptionally linked tothe tbpB gene and required for utilization of transferrin-bound iron [J]. Infect Immun,2000.68:1164-70.
[240]GRAHAM, J.E. and J.E. CLARK-CURTISS, Identification of Mycobacteriumtuberculosis RNAs synthesized in response to phagocytosis by human macrophagesby selective capture of transcribed sequences (SCOTS)[J]. Proc Natl Acad Sci U S A,1999.96:11554-9.
[241]BALTES, N. and G.F. GERLACH, Identification of genes transcribed byActinobacillus pleuropneumoniae in necrotic porcine lung tissue by using selectivecapture of transcribed sequences [J]. Infect Immun,2004.72:6711-6.
[242]ST GEME, J.W.,3RD, D. CUTTER, and S.J. BARENKAMP, Characterizationof the genetic locus encoding Haemophilus influenzae type b surface fibrils [J]. JBacteriol,1996.178:6281-7.
[243]COTTER, S.E., H.J. YEO, T. JUEHNE, et al., Architecture and adhesive activityof the Haemophilus influenzae Hsf adhesin [J]. J Bacteriol,2005.187:4656-64.
[244]GREEN, J., A.D. SHARROCKS, J.I. MACINNES, et al., Purification of HlyX,a potential regulator of haemolysin synthesis, and properties of HlyX:FNR hybrids [J].Proc Biol Sci,1992.248:79-84.
[245]MISTRY, D. and R.A. STOCKLEY, IgA1protease [J]. Int J Biochem Cell Biol,2006.38:1244-8.
[246]RIESBECK, K. and T. NORDSTROM, Structure and immunological action ofthe human pathogen Moraxella catarrhalis IgD-binding protein [J]. Crit Rev Immunol,2006.26:353-76.
[247]MORA, M., D. VEGGI, L. SANTINI, et al., Reverse vaccinology [J]. DrugDiscov Today,2003.8:459-64.
[248]SERRUTO, D. and R. RAPPUOLI, Post-genomic vaccine development [J].FEBS Lett,2006.580:2985-92.
[249]PIZZA, M., V. SCARLATO, V. MASIGNANI, et al., Identification of vaccinecandidates against serogroup B meningococcus by whole-genome sequencing [J].Science,2000.287:1816-20.
[250]CHUNG, J.W., C. NG-THOW-HING, L.I. BUDMAN, et al., Outer membraneproteome of Actinobacillus pleuropneumoniae: LC-MS/MS analyses validate in silicopredictions [J]. Proteomics,2007.7:1854-65.
[251]GRIFANTINI, R., E. BARTOLINI, A. MUZZI, et al., Previously unrecognizedvaccine candidates against group B meningococcus identified by DNAmicroarrays [J].Nat Biotechnol,2002.20:914-21.
[252]BELANGER, M., D. DUBREUIL, J. HAREL, et al., Role oflipopolysaccharides in adherence of Actinobacillus pleuropneumoniae to porcinetracheal rings [J]. Infect Immun,1990.58:3523-30.
[253]PARADIS, S.E., D. DUBREUIL, S. RIOUX, et al., High-molecular-masslipopolysaccharides are involved in Actinobacillus pleuropneumoniae adherence toporcine respiratory tract cells [J]. Infect Immun,1994.62:3311-9.
[254]PARADIS, S.E., J.D. DUBREUIL, M. GOTTSCHALK, et al., Inhibition ofadherence of Actinobacillus pleuropneumoniae to porcine respiratory tract cells bymonoclonal antibodies directed against LPS and partial characterization of the LPSreceptors [J]. Curr Microbiol,1999.39:313-0320.
[255]MAGNUSSON, U., J. BOSSE, B.A. MALLARD, et al., Antibody response toActinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high andlow immune response [J]. Vaccine,1997.15:997-1000.
[256]SHIN, N.R., I.S. CHOI, J.M. KIM, et al., Effective methods for the productionof immunoglobulin Y using immunogens of Bordetella bronchiseptica, Pasteurellamultocida andActinobacillus pleuropneumoniae [J]. J Vet Sci,2002.3:47-57.
[257]RAMJEET, M., V. DESLANDES, J. GOURE, et al., Actinobacilluspleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies[J].Anim Health Res Rev,2008.9:25-45.
[258]THIBOUTOT, D.M., Overview of acne and its treatment [J]. Cutis,2008.81:3-7.
[259]MIYATA, H., K. NOMOTO, and K. TAKEYA, Characteristics of resistance toListeria monocytogenes enhanced by Corynebacterium parvum in mice [J].Immunology,1980.40:33-9.
[260]KIRCHNER, H., H.M. HIRT, and K. MUNK, Protection against herpes simplexvirus infection in mice by Corynebacterium parvum [J]. Infect Immun,1977.16:9-11.
[261]ABEL, L.C., S. CHEN, L.G. RICCA, et al., Adjuvant effect of LPS and killedPropionibacterium acnes on the development of experimental gastrointestinalnematode infestation in sheep [J]. Parasite Immunol,2009.31:604-12.
[262]YANG, P., L.C. LEI, F. XIE, et al., Immune activity of Propionibacterium acnesagainst Actinobacillus pleuropneumoniae infection in mice, in Chinese Journal ofPreventive Veterinary Medicine2009.596-9.
[263]李林溪,雷连成,高宇,等,痤疮丙酸杆菌对小鼠抗胸膜肺炎放线杆菌血清7型9型的免疫保护[J].河北科技师范学院学报,2010.24:4.
[264]MCDOWELL, A., S. VALANNE, G. RAMAGE, et al., Propionibacterium acnestypes I and II represent phylogenetically distinct groups [J]. J Clin Microbiol,2005.43:326-34.
[265]MURRAY, M.G. and W.F. THOMPSON, Rapid isolation of high molecularweight plant DNA[J]. NucleicAcids Res,1980.8:4321-5.
[266]ZHANG, Y., I-TASSER server for protein3D structure prediction [J]. BMCBioinformatics,2008.9:40.
[267]SHEN, H.B. and K.C. CHOU, Gpos-PLoc: an ensemble classifier for predictingsubcellular localization of Gram-positive bacterial proteins [J]. Protein Eng Des Sel,2007.20:39-46.
[268]NASCIMENTO, E., J.O. COSTA, M.P. GUIMARAES, et al., Effective immuneprotection of pigs against cysticercosis [J]. Vet Immunol Immunopathol,1995.45:127-37.
[269]VILELA MDE, C., D.C. GOMES, A. MARQUES-DA-SILVA EDE, et al.,Successful vaccination against Leishmania chagasi infection in BALB/c mice withfreeze-thawed Leishmania antigen and Corynebacterium parvum [J]. Acta Trop,2007.104:133-9.
[270]LYONS, J.A., D.A. BEMIS, M.J. BRYANT, et al., Isolation ofPropionibacterium acnes from a case of placentitis and abortion in a cow [J]. J VetDiagn Invest,2009.21:274-7.
[271]SALANITRO, J.P., I.G. BLAKE, and P.A. MUIRHEAD, Isolation andidentification of fecal bacteria from adult swine [J]. Appl Environ Microbiol,1977.33:79-84.
[272]SQUAIELLA, C.C., A.L. LONGHINI, E.G. BRAGA, et al., Modulation of thetype I hypersensitivity late phase reaction to OVA by Propionibacterium acnes-solublepolysaccharide [J]. Immunol Lett,2008.121:157-66.
[273]WU, L., Structure and functional characterization of single-strand DNA bindingprotein SSDP1: carboxyl-terminal of SSDP1has transcription activity [J]. BiochemBiophys Res Commun,2006.339:977-84.
[274]SHIBUSAWA, Y., Y. INO, T. KINEBUCHI, et al., Purification of single-strandDNA binding protein from an Escherichia coli lysate using counter-currentchromatography, partition and precipitation [J]. J Chromatogr B Analyt TechnolBiomed Life Sci,2003.793:275-9.
[275]CHOU, K.C. and H.B. SHEN, Cell-PLoc: a package of Web servers forpredicting subcellular localization of proteins in various organisms [J]. Nat Protoc,2008.3:153-62.
[276]YUAN, F., J. LIU, Y. GUO, et al., Influences of ORF1on the virulence andimmunogenicity of Actinobacillus pleuropneumoniae [J]. Curr Microbiol,2011.63:574-80.
[277]TURNI, C. and P.J. BLACKALL, An evaluation of the apxIVA based PCR-REAmethod for differentiation of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2007.121:163-9.
[278]WANG, C., Y. WANG, M. SHAO, et al., Positive role for rApxIVN in theimmune protection of pigs against infection by Actinobacillus pleuropneumoniae [J].Vaccine,2009.27:5816-21.
[279]LIU, J., X. CHEN, L. LIN, et al., Potential use an Actinobacilluspleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine thatallows serological differentiation between vaccinated and infected animals [J].Vaccine,2007.25:7696-705.
[280]马三梅,王永飞,绿色荧光蛋白和荧光素酶[J].生物学教学,2005.30:5-6.
[281]GREER, L.F.,3RD and A.A. SZALAY, Imaging of light emission from theexpression of luciferases in living cells and organisms: a review [J]. Luminescence,2002.17:43-74.
[282]杜彦艳,单保恩,报告基因荧光素酶在科研中的应用[J].中华肿瘤防治杂志,2009.16:715-718.
[283]WAIDMANN, M.S., F.S. BLEICHRODT, T. LASLO, et al., Bacterial luciferasereporters: the Swiss army knife of molecular biology [J]. Bioeng Bugs,2011.2:8-16.
[284]HALL, M.P., J. UNCH, B.F. BINKOWSKI, et al., Engineered luciferase reporterfrom a deep sea shrimp utilizing a novel imidazopyrazinone substrate [J]. ACS ChemBiol,2012.7:1848-57.
[285]STAFF, T.S. Top10Innovations2012. The Scientist’s5th installment of itsannual competition attracted submissions from across the life science spectrum.2012.
[286]SONG, G., Q. JIANG, T. XU, et al., A convenient luminescence assay offerroportin internalization to study its interaction with hepcidin [J]. FEBS J,2013.280:1773-81.
[287]BOEKEMA, B.K., J.P. VAN PUTTEN, N. STOCKHOFE-ZURWIEDEN, et al.,Host cell contact-induced transcription of the type IV fimbria gene cluster ofActinobacillus pleuropneumoniae [J]. Infect Immun,2004.72:691-700.
[288]BOSSE, J.T., A.L. DURHAM, A.N. RYCROFT, et al., New plasmid tools forgenetic analysis of Actinobacillus pleuropneumoniae and other pasteurellaceae [J].Appl Environ Microbiol,2009.75:6124-31.
[289]LANGFORD, P.R., B.M. LOYNDS, and J.S. KROLL, Cloning and molecularcharacterization of Cu,Zn superoxide dismutase from Actinobacilluspleuropneumoniae [J]. Infect Immun,1996.64:5035-41.
[290]BOSSE, J.T., J.H. NASH, J.S. KROLL, et al., Harnessing natural transformationin Actinobacillus pleuropneumoniae: a simple method for allelic replacements [J].FEMS Microbiol Lett,2004.233:277-81.
[291]WIDDER, E.A., Bioluminescence in the ocean: origins of biological, chemical,and ecological diversity [J]. Science,2010.328:704-8.
[292]MELNICK, J.S., J. JANES, S. KIM, et al., An efficient rapid system forprofiling the cellular activities of molecular libraries [J]. Proc Natl Acad Sci U S A,2006.103:3153-8.
[293]DOSHI, U. and A.P. LI, Luciferin IPA-based higher throughput humanhepatocyte screening assays for CYP3A4inhibition and induction [J]. J BiomolScreen,2011.16:903-9.
[294]SMIRNOVA, N.A., R.E. HASKEW-LAYTON, M. BASSO, et al., Developmentof Neh2-luciferase reporter and its application for high throughput screening andreal-time monitoring of Nrf2activators [J]. Chem Biol,2011.18:752-65.
[295]PERROY, J., S. PONTIER, P.G. CHAREST, et al., Real-time monitoring ofubiquitination in living cells by BRET [J]. Nat Methods,2004.1:203-8.
[296]REMY, I. and S.W. MICHNICK, A highly sensitive protein-protein interactionassay based on Gaussia luciferase [J]. Nat Methods,2006.3:977-9.
[297]TANNOUS, B.A., D.E. KIM, J.L. FERNANDEZ, et al., Codon-optimizedGaussia luciferase cDNA for mammalian gene expression in culture and in vivo [J].Mol Ther,2005.11:435-43.
[298]MARKOVA, S.V., S. GOLZ, L.A. FRANK, et al., Cloning and expression ofcDNA for a luciferase from the marine copepod Metridia longa. A novel secretedbioluminescent reporter enzyme [J]. J Biol Chem,2004.279:3212-7.
[299]NAKAJIMA, Y., K. KOBAYASHI, K. YAMAGISHI, et al., cDNA cloning andcharacterization of a secreted luciferase from the luminous Japanese ostracod,Cypridina noctiluca [J]. Biosci Biotechnol Biochem,2004.68:565-70.
[300]SUZUKI, C., Y. NAKAJIMA, H. AKIMOTO, et al., A new additional reporterenzyme, dinoflagellate luciferase, for monitoring of gene expression in mammaliancells [J]. Gene,2005.344:61-6.
[301]INOUYE, S., K. WATANABE, H. NAKAMURA, et al., Secretional luciferaseof the luminous shrimp Oplophorus gracilirostris: cDNA cloning of a novelimidazopyrazinone luciferase(1)[J]. FEBS Lett,2000.481:19-25.
[302]WURDINGER, T., C. BADR, L. PIKE, et al., A secreted luciferase for ex vivomonitoring of in vivo processes [J]. Nat Methods,2008.5:171-3.
[303]ANDREU, N., A. ZELMER, T. FLETCHER, et al., Optimisation ofbioluminescent reporters for use with mycobacteria [J]. PLoS One,2010.5: e10777.
[304]SHIMOMURA, O., T. MASUGI, F.H. JOHNSON, et al., Properties and reactionmechanism of the bioluminescence system of the deep-sea shrimp Oplophorusgracilorostris [J]. Biochemistry,1978.17:994-8.
[305]SONG, G., Q. JIANG, T. XU, et al., A convenient luminescence assay offerroportin internalization to study its interaction with hepcidin [J]. FEBS J,2013.
[306]SLEIGHT, S.C., B.A. BARTLEY, J.A. LIEVIANT, et al., In-Fusion BioBrickassembly and re-engineering [J]. NucleicAcids Res,2010.38:2624-36.
[307]WANG, Y., S.D. GOODMAN, R.J. REDFIELD, et al., Natural transformationand DNA uptake signal sequences in Actinobacillus actinomycetemcomitans [J]. JBacteriol,2002.184:3442-9.
[308]JANSEN, R., J. BRIAIRE, H.E. SMITH, et al., Knockout mutants ofActinobacillus pleuropneumoniae serotype1that are devoid of RTX toxins do notactivate or kill porcine neutrophils [J]. Infect Immun,1995.63:27-37.
[309]WARD, C.K., M.L. LAWRENCE, H.P. VEIT, et al., Cloning and mutagenesis ofa serotype-specific DNA region involved in encapsulation and virulence ofActinobacillus pleuropneumoniae serotype5a: concomitant expression of serotype5aand1capsular polysaccharides in recombinant A. pleuropneumoniae serotype1[J].Infect Immun,1998.66:3326-36.
[310]OSWALD, W., W. TONPITAK, G. OHRT, et al., A single-step transconjugationsystem for the introduction of unmarked deletions into Actinobacilluspleuropneumoniae serotype7using a sucrose sensitivity marker [J]. FEMS MicrobiolLett,1999.179:153-60.
[311]LIU, J., X. CHEN, C. TAN, et al., In vivo induced RTX toxin ApxIVA isessential for the full virulence of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2009.137:282-9.
[312]EAMENS, G.J., J.R. GONSALVES, A.M. WHITTINGTON, et al., Evaluationof serovar-independent ELISA antigens of Actinobacillus pleuropneumoniae in pigs,following experimental challenge with A. pleuropneumoniae, Mycoplasmahyopneumoniae and Pasteurella multocida [J].Aust Vet J,2012.90:225-34.
[313]CHO, W.S., C. CHOI, and C. CHAE, In situ hybridization for the detection ofthe apxIV gene in the lungs of pigs experimentally infected with twelveActinobacillus pleuropneumoniae serotypes [J]. Vet Res,2002.33:653-60.
[314]HU, D., H. HAN, R. ZHOU, et al., Gold(III) enhanced chemiluminescenceimmunoassay for detection of antibody against ApxIV of Actinobacilluspleuropneumoniae [J].Analyst,2008.133:768-73.
[315]TOBIAS, T.J., A. BOUMA, D. KLINKENBERG, et al., Detection ofActinobacillus pleuropneumoniae in pigs by real-time quantitative PCR for theapxIVAgene [J]. Vet J,2012.193:557-60.
[316]FERRIERES, L., G. HEMERY, T. NHAM, et al., Silent mischief: bacteriophageMu insertions contaminate products of Escherichia coli random mutagenesisperformed using suicidal transposon delivery plasmids mobilized by broad-host-rangeRP4conjugative machinery [J]. J Bacteriol,2010.192:6418-27.
[317]GORYSHIN, I.Y., J. JENDRISAK, L.M. HOFFMAN, et al., Insertionaltransposon mutagenesis by electroporation of released Tn5transposition complexes[J]. Nat Biotechnol,2000.18:97-100.
[318]HAYES, F., Transposon-based strategies for microbial functional genomics andproteomics [J].Annu Rev Genet,2003.37:3-29.
[319]HOFFMAN, L.M., J.J. JENDRISAK, R.J. MEIS, et al., Transposome insertionalmutagenesis and direct sequencing of microbial genomes [J]. Genetica,2000.108:19-24.
[320]CHIANG, S.L. and E.J. RUBIN, Construction of a mariner-based transposon forepitope-tagging and genomic targeting [J]. Gene,2002.296:179-85.
[321]MILLER, V.L. and J.J. MEKALANOS, A novel suicide vector and its use inconstruction of insertion mutations: osmoregulation of outer membrane proteins andvirulence determinants in Vibrio cholerae requires toxR [J]. J Bacteriol,1988.170:2575-83.
[322]SERINA, S., F. NOZZA, G. NICASTRO, et al., Scanning the Escherichia colichromosome by random transposon mutagenesis and multiple phenotypic screening[J]. Res Microbiol,2004.155:692-701.
[323]THOMAS, C.M. and C.A. SMITH, Incompatibility group P plasmids: genetics,evolution, and use in genetic manipulation [J]. Annu Rev Microbiol,1987.41:77-101.
[324]FIGURSKI, D.H. and D.R. HELINSKI, Replication of an origin-containingderivative of plasmid RK2dependent on a plasmid function provided in trans [J]. ProcNatlAcad Sci U SA,1979.76:1648-52.
[325]GROISMAN, E.A., In vivo genetic engineering with bacteriophage Mu [J].Methods Enzymol,1991.204:180-212.
[326]SIMON, R., U. PRIEFER, and A. P HLER, A broad host range mobilizationsystem for in vivo genetic engineering: transposon mutagenesis in Gram negativebacteria [J]. Biotechnology,1983.1:784-791.
[327]DE LORENZO, V. and K.N. TIMMIS, Analysis and construction of stablephenotypes in gram-negative bacteria with Tn5-and Tn10-derived minitransposons[J]. Methods Enzymol,1994.235:386-405.
[328]HUNSTAD, D.A., S.S. JUSTICE, C.S. HUNG, et al., Suppression of bladderepithelial cytokine responses by uropathogenic Escherichia coli [J]. Infect Immun,2005.73:3999-4006.
[329]MOXLEY, R.A., E.M. BERBEROV, D.H. FRANCIS, et al., Pathogenicity of anenterotoxigenic Escherichia coli hemolysin (hlyA) mutant in gnotobiotic piglets [J].Infect Immun,1998.66:5031-5.
[330]LAWLEY, T.D., K. CHAN, L.J. THOMPSON, et al., Genome-wide screen forSalmonella genes required for long-term systemic infection of the mouse [J]. PLoSPathog,2006.2: e11.
[331]POBIGAYLO, N., D. WETTER, S. SZYMCZAK, et al., Construction of a largesignature-tagged mini-Tn5transposon library and its application to mutagenesis ofSinorhizobium meliloti [J].Appl Environ Microbiol,2006.72:4329-37.
[332]ZHANG, X.X. and P.B. RAINEY, Dual involvement of CbrAB and NtrBC in theregulation of histidine utilization in Pseudomonas fluorescens SBW25[J]. Genetics,2008.178:185-95.
[333]PEMBERTON, C.L., N.A. WHITEHEAD, M. SEBAIHIA, et al., Novelquorum-sensing-controlled genes in Erwinia carotovora subsp. carotovora:identification of a fungal elicitor homologue in a soft-rotting bacterium [J]. Mol PlantMicrobe Interact,2005.18:343-53.
[334]BABIC, A., A.M. GUEROUT, and D. MAZEL, Construction of an improvedRP4(RK2)-based conjugative system [J]. Res Microbiol,2008.159:545-9.
[335]LETOFFE, S., P. DELEPELAIRE, and C. WANDERSMAN, The housekeepingdipeptide permease is the Escherichia coli heme transporter and functions with twooptional peptide binding proteins [J]. Proc NatlAcad Sci U SA,2006.103:12891-6.
[336]LONE, A.G., V. DESLANDES, J.H. NASH, et al., Modulation of geneexpression in Actinobacillus pleuropneumoniae exposed to bronchoalveolar fluid [J].PLoS One,2009.4: e6139.
[337]BUETTNER, F.F., S.A. KONZE, A. MAAS, et al., Proteomic andimmunoproteomic characterization of a DIVA subunit vaccine against Actinobacilluspleuropneumoniae [J]. Proteome Sci,2011.9:23.
[338]COLEMAN, H.N., D.A. DAINES, J. JARISCH, et al., Chemically definedmedia for growth of Haemophilus influenzae strains [J]. J Clin Microbiol,2003.41:4408-10.
[339]WELCH, R.A., M.E. BAUER, A.D. KENT, et al., Battling against hostphagocytes: the wherefore of the RTX family of toxins?[J]. Infect Agents Dis,1995.4:254-72.
[340]刘金林,胸膜肺炎放线杆菌毒素ApxIV的致病性及基因缺失弱毒疫苗的研究,2009,华中农业大学.
[341]CHIEN, M.S., Y.Y. CHAN, Z.W. CHEN, et al., Actinobacilluspleuropneumoniae serotype10derived ApxI induces apoptosis in porcine alveolarmacrophages [J]. Vet Microbiol,2009.135:327-33.
[342]VANDEN BERGH, P.G., L.L. ZECCHINON, T. FETT, et al., Porcine CD18mediates Actinobacillus pleuropneumoniae ApxIII species-specific toxicity [J]. VetRes,2009.40:33.
[343]ANDERSON, T.J. and J.I. MACINNES, Expression and phylogeneticrelationships of a novel lacZ homologue from Actinobacillus pleuropneumoniae [J].FEMS Microbiol Lett,1997.152:117-23.
[344]DREYFUS, A., A. SCHALLER, S. NIVOLLET, et al., Use of recombinantApxIV in serodiagnosis of Actinobacillus pleuropneumoniae infections, developmentand prevalidation of the ApxIV ELISA[J]. Vet Microbiol,2004.99:227-38.
[345]HSU, Y.M., N. CHIN, C.F. CHANG, et al., Cloning and characterization of theActinobacillus pleuropneumoniae fur gene and its role in regulation of ApxI andAfuABC expression [J]. DNASeq,2003.14:169-81.
[346]BAUER, M.E. and R.A. WELCH, Association of RTX toxins with erythrocytes[J]. Infect Immun,1996.64:4665-72.
[347]OSICKA, R., K. PROCHAZKOVA, M. SULC, et al., A novel "clip-and-link"activity of repeat in toxin (RTX) proteins from gram-negative pathogens. Covalentprotein cross-linking by an Asp-Lys isopeptide bond upon calcium-dependentprocessing at anAsp-Pro bond [J]. J Biol Chem,2004.279:24944-56.
[2]白洁，顾威，王真子，随静,等,痤疮皮损内菌群的分离与研究[J].中国微生态学杂志,2005.17(6).
[3]MCDOWELL, A., A.L. PERRY, P.A. LAMBERT, et al., Anew phylogenetic groupof Propionibacterium acnes [J]. J Med Microbiol,2008.57:218-24.
[4]HALL, G.S., K. PRATT-RIPPIN, D.M. MEISLER, et al., Growth curve forPropionibacterium acnes [J]. Curr Eye Res,1994.13:465-6.
[5]姜春明，葛蒙梁,痤疮的发病机制研究进展[J].皮肤病与性病,2003.25:16-18.
[6]崔秀珍,傅志强,曲云英, MEBO抗菌作用实验研究[J].中国烧伤创伤杂志,1998.4:15-17.
[7]JAPPE, U., Pathological mechanisms of acne with special emphasis onPropionibacterium acnes and related therapy [J]. Acta Derm Venereol,2003.83:241-8.
[8]王大光，朱文元,痤疮发病机制中炎症的研究进展[J].中国美容医学,2004.13:3.
[9]STEINER, B., S. ROMERO-STEINER, D. CRUCE, et al., Cloning andsequencing of the hyaluronate lyase gene from Propionibacterium acnes [J]. Can JMicrobiol,1997.43:315-21.
[10]高天文,痤疮丙酸杆菌相关疾病[J].中国美容医学,2005.14(4).
[11]ALDAVE, A.J., J.D. STEIN, V.A. DERAMO, et al., Treatment strategies forpostoperative Propionibacterium acnes endophthalmitis [J]. Ophthalmology,1999.106:2395-401.
[12]HARRIS, A.E., C. HENNICKE, K. BYERS, et al., Postoperative discitis due toPropionibacterium acnes: a case report and review of the literature [J]. Surg Neurol,2005.63:538-41; discussion541.
[13]TUNNEY, M.M., PATRICK, S., CURRAN, M.D., RAMAGE, G., HANNA,D.,NIXON, J.R., GORMAN, S.P., DAVIS, R.I. ET AL, Detection of prosthetic hipinfection at revision arthroplasty by immunofluorescence microscopy and PCRamplification of the bacterial16S rRNA gene [J]. J Clin Microbiol,1999.37:3281–3290.
[14]ABOLNIK, I.Z., J.V. EATON, and D.J. SEXTON, Propionibacterium acnesvertebral osteomyelitis following lumbar puncture: case report and review [J]. ClinInfect Dis,1995.21:694-5.
[15]ZARATE, M.S., D. YAHNI, M. GUEVARA, et al.,[Post-surgery cerebral abscessdue to Propionibacterium acnes.][J]. Medicina (BAires),2009.69:170-2.
[16]朱莲花,痤疮丙酸杆菌在痤疮发病中的作用[J].中国美容医学,2006.15:476-477.
[17]COGEN, A.L., V. NIZET, and R.L. GALLO, Skin microbiota: a source of diseaseor defence?[J]. Br J Dermatol,2008.158:442-55.
[18]MIESCHER, S., M.P. STIERLI, M. TEUBER, et al., Propionicin SM1, abacteriocin from Propionibacterium jensenii DF1: isolation and characterization of theprotein and its gene [J]. SystAppl Microbiol,2000.23:174-84.
[19]FAYE, T., T. LANGSRUD, I.F. NES, et al., Biochemical and geneticcharacterization of propionicin T1, a new bacteriocin from Propionibacterium thoenii[J].Appl Environ Microbiol,2000.66:4230-6.
[20]FUJIMURA, S. and T. NAKAMURA, Purification and properties of abacteriocin-like substance (acnecin) of oral Propionibacterium acnes [J]. AntimicrobAgents Chemother,1978.14:893-8.
[21]ADLAM, C., E.S. BROUGHTON, and M.T. SCOTT, Enhanced resistance ofmice to infection with bacteria following pre-treatment with Corynebacterium parvum[J]. Nat New Biol,1972.235:219-20.
[22]SLJIVIC, V.S. and S.R. WATSON, The adjuvant effect of Corynebacteriumparvum: T-cell dependence of macrophage activation [J]. J Exp Med,1977.145:45-57.
[23]OKAMURA, H., M. WADA, K. NAGATA, et al., Induction of murine gammainterferon production by lipopolysaccharide and interleukin-2in Propionibacteriumacnes-induced peritoneal exudate cells [J]. Infect Immun,1987.55:335-41.
[24]OKAMURA H, N.K., KOMATSU T, TANIMOTO T, NUKATA Y, TANABE F,AKITA K, TORIGOE K, OKURA T, FUKUDA S,, A novel costimulatory factor forgamma interferon induction found in the livers of mice causes endotoxic shock [J].Infect Immun,1995.63:3966-3972.
[25]SCHORLEMMER, H.U., D. BITTER-SUERMANN, and A.C. ALLISON,Complement activation by the alternative pathway and macrophage enzyme secretionin the pathogenesis of chronic inflammation [J]. Immunology,1977.32:929-40.
[26]王世若,王兴龙,韩文瑜,现代动物免疫学2001:吉林科学技术出版社.393.
[27]ROSSI, G.A., R. FELLETTI, B. BALBI, et al., Symptomatic treatment ofrecurrent malignant pleural effusions with intrapleurally administeredCorynebacterium parvum. Clinical response is not associated with evidence ofenhancement of local cellular-mediated immunity [J]. Am Rev Respir Dis,1987.135:885-90.
[28]TAKEDA, K., T. KAISHO, and S. AKIRA, Toll-like receptors [J]. Annu RevImmunol,2003.21:335-76.
[29]AKIRA, S. and K. TAKEDA, Toll-like receptor signalling [J]. Nat Rev Immunol,2004.4:499-511.
[30]IWASAKI, A. and R. MEDZHITOV, Toll-like receptor control of the adaptiveimmune responses [J]. Nat Immunol,2004.5:987-95.
[31]VAN DUIN, D., R. MEDZHITOV, and A.C. SHAW, Triggering TLR signaling invaccination [J]. Trends Immunol,2006.27:49-55.
[32]KAISHO, T. and S. AKIRA, Toll-like receptors as adjuvant receptors [J]. BiochimBiophys Acta,2002.1589:1-13.
[33]JUGEAU, S., I. TENAUD, A.C. KNOL, et al., Induction of toll-like receptors byPropionibacterium acnes [J]. Br J Dermatol,2005.153:1105-13.
[34]TSUJI, S., M. MATSUMOTO, O. TAKEUCHI, et al., Maturation of humandendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin:involvement of toll-like receptors [J]. Infect Immun,2000.68:6883-90.
[35]KALIS, C., M. GUMENSCHEIMER, N. FREUDENBERG, et al., Requirementfor TLR9in the immunomodulatory activity of Propionibacterium acnes [J]. JImmunol,2005.174:4295-300.
[36]孙彬裕,高尚先,短小棒状杆菌CpG-DNA提取方法的研究[J].药物分析杂志,2009.29:4.
[37]IVAN M. ROITT, P.J.D., Roitt's Essential Immunology.10ed2001: BlackwellPublishing Ltd.481.
[38]MEGID, J., M.T. PERACOLLI, P.R. CURI, et al., Effect of vaccination and theimmunomodulators "bacillus of Calmette-Guerin, avridine and Propionibacteriumacnes" on rabies in mice [J]. Comp Immunol Microbiol Infect Dis,1998.21:305-18.
[39]MEGID, J. and R. KANENO, Natural killer activity in mice infected with rabiesvirus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator [J].Comp Immunol Microbiol Infect Dis,2000.23:91-7.
[40]MEGID, J., D.N. CREMONINI, and H. LEOMIL, Distribution of rabies virus ininfected mice, vaccinated and submitted to P. acnes as immunomodulator [J]. CompImmunol Microbiol Infect Dis,2002.25:237-48.
[41]MEGID, J., R. KANENO, C.N. NOZAKI, et al., Increased interleukin-10associated with low IL-6concentration correlated with greater survival rates in miceinfected by rabies virus vaccinated against it and immunomodulated with P. acnes [J].Comp Immunol Microbiol Infect Dis,2004.27:393-411.
[42]ROSSOL, S., R. VOTH, S. BRUNNER, et al., Corynebacterium parvum(Propionibacterium acnes): an inducer of tumor necrosis factor-alpha in humanperipheral blood mononuclear cells and monocytes in vitro [J]. Eur J Immunol,1990.20:1761-5.
[43]JUNG, Y.S., S.E. MATSUMOTO, M. YAMASHITA, et al., Propionibacteriumacnes acts as an adjuvant in in vitro immunization of human peripheral bloodmononuclear cells [J]. Biosci Biotechnol Biochem,2007.71:1963-9.
[44]MUSSALEM, J.S., J.R.C. VASCONCELOS, C.C. SQUAIELLA, et al., Adjuvanteffect of the propionibacterium acnes and its purified soluble polysaccharide on theimmunization with plasmidial DNA containing a Trypanosoma cruzi gene [J].Microbiology and Immunology,2006.50:253-263.
[45]SQUAIELLA, C.C., A.L. LONGHINI, E.G. BRAGA, et al., Modulation of thetype I hypersensitivity late phase reaction to OVA by Propionibacterium acnes-solublepolysaccharide [J]. Immunol Lett,2008.
[46]杨琳,白春杰,崔岩,短棒状菌菌体细胞与细胞代谢产物生物学活性的比较[J].药物生物技术,2005.12:3.
[47]DAWES, J., S.J. TUACH, and W.H. MCBRIDE, Properties of an antigenicpolysaccharide from Corynebacterium parvum [J]. J Bacteriol,1974.120:24-30.
[48]CANTRELL, J.L. and R.W. WHEAT, Antitumor activity and lymphoreticularstimulation properties of fractions isolated from Corynebacterium parvum [J]. CancerRes,1979.39:3554-63.
[49]JULAK, J., M. BEDNAR, F. TURECEK, et al., Fatty acid composition of aPropionibacterium acnes vaccine and its relationship to immunostimulatory activity[J]. Zentralbl Bakteriol Mikrobiol Hyg [A],1984.258:296-309.
[50]MARA, M., J. JULAK, M. BEDNAR, et al., The influence of Propionibacteriumacnes (Corynebacterium parvum) fractions on immune response in vivo [J]. ZentralblBakteriol,1994.281:549-55.
[51]虢国泰,刘宝昌,路松毅,短小棒菌细胞壁对小鼠粒系造血祖细胞的增殖作用[J].中国现代实用医学杂志,2005.4:2.
[52]王宇宏,高航,倪维华,等,短棒状杆菌有效成分的分离及其作用[J].中国生物制品学杂志,2005.18:2.
[53]安鸿志and袁现明,新编抗肿瘤药物手册2003:河南科学技术出版社.284.
[54]BAST, R.C., JR., J.S. BEREK, R. OBRIST, et al., Intraperitoneal immunotherapyof human ovarian carcinoma with Corynebacterium parvum [J]. Cancer Res,1983.43:1395-401.
[55]WOODRUFF, M. and P. WALBAUM, A phase-II trial of Corynebacteriumparvum as adjuvant to surgery in the treatment of operable lung cancer [J]. CancerImmunol Immunother,1983.16:114-6.
[56]LA COUR PETERSEN, E., P. HOKLAND, and J. ELLEGAARD, Adjuvantimmune stimulation with Corynebacterium parvum during maintenancechemotherapy of acute myeloid leukemia. Aprospective randomized study [J]. CancerImmunol Immunother,1983.16:88-92.
[57]LISSONI, P., S. BARNI, A. ARDIZZOIA, et al., Intracavitary administration ofinterleukin-2as palliative therapy for neoplastic effusions [J]. Tumori,1992.78:118-20.
[58]TIZARD.I, Round-Table Discussion Eqstim Immunostimulant, in37AnnualAAEP Meeting1992, J Equine Vet Sci.209-14.
[59]王海华,盛银平,曹义虎,等,鱼用免疫增强剂的作用机制及其应用研究进展[J].兽药与饲料添加剂,2005.10:3.
[60]FLAMINIO, M.J., B.R. RUSH, and W. SHUMAN, Immunologic function inhorses after non-specific immunostimulant administration [J]. Vet ImmunolImmunopathol,1998.63:303-15.
[61]DAVIS, E.G., B.R. RUSH, and F. BLECHA, Increases in cytokine andantimicrobial peptide gene expression in horses by immunomodulation withPropionibacterium acnes [J]. Vet Ther,2003.4:5-11.
[62]ISEKI, H., N. TAKABATAKE, N. OTA, et al., Babesia: the protective effects ofkilled Propionibacterium acnes on the infections of two rodent Babesia parasites inmice [J]. Exp Parasitol,2008.118:543-8.
[63]HOGAN, J.S., K.L. SMITH, D.A. TODHUNTER, et al., Efficacy of dry cowtherapy and a Propionibacterium acnes product in herds with low somatic cell count[J]. J Dairy Sci,1994.77:3331-7.
[64]HOGAN, J.S., K.L. SMITH, D.A. TODHUNTER, et al., Therapy ofexperimentally induced coliform mastitis with a Propionibacterium acnes product [J].J Dairy Sci,1994.77:462-7.
[65]DINSMORE, R.P., M.B. CATTELL, R.D. STEVENS, et al., Efficacy of aPropionibacterium acnes immunostimulant for treatment of chronic Staphylococcusaureus mastitis [J]. J Dairy Sci,1995.78:1932-6.
[66]周晨阳，刘海燕，杨发龙,新型免疫佐剂研究进展[J].现代畜牧兽医,2007:76-78.
[67]高尚先,宋静,刘星霞,等,无细胞短棒状杆菌纳米级制剂抗肿瘤作用及机理[J].中国肿瘤生物治疗杂志,2003.10:4.
[68]GAO, S., C. LIU, S. QU, et al., Non-cell Corynebacterium parvum generated bynanotechnology: a promising immunomodulator with less side effects [J]. IntImmunopharmacol,2007.7:1334-42.
[69]高尚先,李守悌,一种短棒状杆菌制剂或无细胞短棒状杆菌制剂在制备治疗HIV感染或爱滋病药剂中的应用, in中国药品生物制品检定所,知识产权出版社,Editor2005,北京元中知识产权代理有限责任公司:中国.18.
[70]PATTISON, I.H., D.G. HOWELL, and J. ELLIOT, A Haemophilus-like organismisolated from pig lung and the associated pneumonic lesions [J]. J Comp Pathol,1957.67:320-30.
[71]DOM, P. and F. HAESEBROUCK, Comparative virulence of NAD-dependentand NAD-independent Actinobacillus pleuropneumoniae strains [J]. ZentralblVeterinarmed B,1992.39:303-6.
[72]雷连成,韩文瑜,孙长江,等,胸膜肺炎放线杆菌血清型特异的疫苗候选基因的筛选及痤疮丙酸杆菌异源免疫[J].中国生物制品学杂志,2008.21:5.
[73]LEI, L., C. SUN, S. LU, et al., Selection of serotype-specific vaccine candidategenes in Actinobacillus pleuropneumoniae and heterologous immunization withPropionibacterium acnes [J]. Vaccine,2008.26:6274-80.
[74]BRUGGEMANN, H., A. HENNE, F. HOSTER, et al., The complete genomesequence of Propionibacterium acnes, a commensal of human skin [J]. Science,2004.305:671-3.
[75]谢芳,胸膜肺炎放线杆菌1型3型差异基因及两种蛋白功能研究,2010,吉林大学.158.
[76]王天奇,董发明,龙塔,洛阳地区规模化猪场传染性胸膜肺炎的血清学调查[J].中国兽医杂志,2006.42:28-29.
[77]樊祜卿,储岳峰,贺英,等,四川省部分地区猪传染性胸膜肺炎的流行病学调查[J].中国动物检疫,2009.26:49-50.
[78]BISGAARD, M., Ecology and significance of Pasteurellaceae in animals [J].Zentralbl Bakteriol,1993.279:7-26.
[79]NEGRETE-ABASCAL, E., M.E. REYES, R.M. GARCIA, et al., Flagella andMotility inActinobacillus pleuropneumoniae [J]. J Bacteriol,2003.185:664-8.
[80]蔡宝祥,猪传染性胸膜肺炎的诊断与防治[J].辽宁畜牧兽医,1996:41-42.
[81]NIELSEN, R., L.O. ANDRESEN, T. PLAMBECK, et al., Serologicalcharacterization of Actinobacillus pleuropneumoniae biotype2strains isolated frompigs in two Danish herds [J]. Vet Microbiol,1997.54:35-46.
[82]PERRY, M.B., Structural analysis of the lipopolysaccharide of Actinobacillus(Haemophilus) pleuropneumoniae serotype10[J]. Biochem Cell Biol,1990.68:808-10.
[83]KOMAL, J.P. and K.R. MITTAL, Grouping of Actinobacillus pleuropneumoniaestrains of serotypes1through12on the basis of their virulence in mice [J]. VetMicrobiol,1990.25:229-40.
[84]JACOBSEN, M.J., J.P. NIELSEN, and R. NIELSEN, Comparison of virulence ofdifferent Actinobacillus pleuropneumoniae serotypes and biotypes using an aerosolinfection model [J]. Vet Microbiol,1996.49:159-68.
[85]CRUIJSEN, T., L.A. VAN LEENGOED, M. HAM-HOFFIES, et al.,Convalescent pigs are protected completely against infection with a homologousActinobacillus pleuropneumoniae strain but incompletely against aheterologous-serotype strain [J]. Infect Immun,1995.63:2341-3.
[86]TADJINE, M. and K.R. MITTAL, Study of antigenic heterogeneity amongActinobacillus pleuropneumoniae serotype7strains [J]. Vet Microbiol,2001.78:49-60.
[87]GAGNE, A., S. LACOUTURE, A. BROES, et al., Development of animmunomagnetic method for selective isolation of Actinobacillus pleuropneumoniaeserotype1from tonsils [J]. J Clin Microbiol,1998.36:251-4.
[88]ANGEN, O., P.M. HEEGAARD, D.T. LAVRITSEN, et al., Isolation ofActinobacillus pleuropneumoniae serotype2by immunomagnetic separation [J]. VetMicrobiol,2001.79:19-29.
[89]MITTAL, K.R., R. HIGGINS, and S. LARIVIERE, Determination of antigenicspecificity and relationship among Haemophilus pleuropneumoniae serotypes by anindirect hemagglutination test [J]. J Clin Microbiol,1983.17:787-90.
[90]MITTAL, K.R., Cross-reactions between Actinobacillus (Haemophilus)pleuropneumoniae strains of serotypes1and9[J]. J Clin Microbiol,1990.28:535-9.
[91]MITTAL, K.R., R. HIGGINS, and S. LARIVIERE, Serological studies ofActinobacillus (Haemophilus) pleuropneumoniae strains of serotype6and theirantigenic relationship with other serotypes [J]. Vet Rec,1988.122:199-203.
[92]INZANA, T.J., J. TODD, C. KOCH, et al., Serotype specificity of immunologicalassays for the capsular polymer of Actinobacillus pleuropneumoniae serotypes1and9[J]. Vet Microbiol,1992.31:351-62.
[93]MITTAL, K.R. and S. BOURDON, Cross-reactivity and antigenic heterogeneityamong Actinobacillus pleuropneumoniae strains of serotypes4and7[J]. J ClinMicrobiol,1991.29:1344-7.
[94]NICOLET, J., P. PAROZ, M. KRAWINKLER, et al., An enzyme-linkedimmunosorbent assay, using an EDTA-extracted antigen for the serology ofHaemophilus pleuropneumoniae [J].Am J Vet Res,1981.42:2139-42.
[95]TROTTIER, Y.L., P.F. WRIGHT, and S. LARIVIERE, Optimization andstandardization of an enzyme-linked immunosorbent assay protocol for serodiagnosisofActinobacillus pleuropneumoniae serotype5[J]. J Clin Microbiol,1992.30:46-53.
[96]FREY, J., M. BECK, J.F. VAN DEN BOSCH, et al., Development of an efficientPCR method for toxin typing of Actinobacillus pleuropneumoniae strains [J]. MolCell Probes,1995.9:277-82.
[97]GRAM, T. and P. AHRENS, Improved diagnostic PCR assay for Actinobacilluspleuropneumoniae based on the nucleotide sequence of an outer membranelipoprotein [J]. J Clin Microbiol,1998.36:443-8.
[98]SCHALLER, A., S.P. DJORDJEVIC, G.J. EAMENS, et al., Identification anddetection of Actinobacillus pleuropneumoniae by PCR based on the gene apxIVA [J].Vet Microbiol,2001.79:47-62.
[99]YANG, W., C. PIN, G. HAIBING, et al., Loop-mediated isothermal amplificationtargeting the apxIVA gene for detection of Actinobacillus pleuropneumoniae [J].FEMS Microbiol Lett,2009.300:83-9.
[100]DE LA PUENTE-REDONDO, V.A., N.G. DEL BLANCO, C.B.GUTIERREZ-MARTIN, et al., Detection and subtyping of Actinobacilluspleuropneumoniae strains by PCR-RFLP analysis of the tbpA and tbpB genes [J]. ResMicrobiol,2000.151:669-81.
[101]GRAM, T., P. AHRENS, M. ANDREASEN, et al., An Actinobacilluspleuropneumoniae PCR typing system based on the apx and omlA genes--evaluationof isolates from lungs and tonsils of pigs [J]. Vet Microbiol,2000.75:43-57.
[102]JESSING, S.G., O. ANGEN, and T.J. INZANA, Evaluation of a multiplex PCRtest for simultaneous identification and serotyping of Actinobacilluspleuropneumoniae serotypes2,5, and6[J]. J Clin Microbiol,2003.41:4095-100.
[103]SCHUCHERT, J.A., T.J. INZANA, O. ANGEN, et al., Detection andidentification of Actinobacillus pleuropneumoniae serotypes1,2, and8by multiplexPCR [J]. J Clin Microbiol,2004.42:4344-8.
[104]ANGEN, O., P. AHRENS, and S.G. JESSING, Development of a multiplex PCRtest for identification of Actinobacillus pleuropneumoniae serovars1,7, and12[J].Vet Microbiol,2008.132:312-8.
[105]ZHOU, L., S.C. JONES, O. ANGEN, et al., Multiplex PCR that can distinguishbetween immunologically cross-reactive serovar3,6, and8Actinobacilluspleuropneumoniae strains [J]. J Clin Microbiol,2008.46:800-3.
[106]ITO, H., Development of a cps-based multiplex PCR for typing of actinobacilluspleuropneumoniae serotypes1,2and5[J]. J Vet Med Sci,2010.72:653-5.
[107]XIAO, G., S. CAO, X. HUANG, et al., DNA microarray-based identification andtyping ofActinobacillus pleuropneumoniae [J]. Can J Vet Res,2009.73:190-9.
[108]TAYLOR, D., B. STRAW, S. D'ALLAIRE, et al., Diseases of Swine.8ed, ed.Ames1999: Iowa State University Press.
[109]MOLLER, K., L.V. ANDERSEN, G. CHRISTENSEN, et al., Optimalization ofthe detection of NAD dependent Pasteurellaceae from the respiratory tract ofslaughterhouse pigs [J]. Vet Microbiol,1993.36:261-71.
[110]SIDIBE, M., S. MESSIER, S. LARIVIERE, et al., Detection of Actinobacilluspleuropneumoniae in the porcine upper respiratory tract as a complement toserological tests [J]. Can J Vet Res,1993.57:204-8.
[111]DUBREUIL, J.D., M. JACQUES, K.R. MITTAL, et al., Actinobacilluspleuropneumoniae surface polysaccharides: their role in diagnosis andimmunogenicity [J].Anim Health Res Rev,2000.1:73-93.
[112]BLACKALL, P.J., H.L. KLAASEN, H. VAN DEN BOSCH, et al., Proposal of anew serovar of Actinobacillus pleuropneumoniae: serovar15[J]. Vet Microbiol,2002.84:47-52.
[113]FREY, J., Virulence in Actinobacillus pleuropneumoniae and RTX toxins [J].Trends Microbiol,1995.3:257-61.
[114]JACQUES, M., Role of lipo-oligosaccharides and lipopolysaccharides inbacterial adherence [J]. Trends Microbiol,1996.4:408-9.
[115]RAMJEET, M., V. DESLANDES, F. ST MICHAEL, et al., Truncation of thelipopolysaccharide outer core affects susceptibility to antimicrobial peptides andvirulence of Actinobacillus pleuropneumoniae serotype1[J]. J Biol Chem,2005.280:39104-14.
[116]HAESEBROUCK, F., K. CHIERS, I. VAN OVERBEKE, et al., Actinobacilluspleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis andprotection [J]. Vet Microbiol,1997.58:239-49.
[117]JACQUES, M., Surface polysaccharides and iron-uptake systems ofActinobacillus pleuropneumoniae [J]. Can J Vet Res,2004.68:81-5.
[118]BACKSTROM, L., Present uses of and experiences with swine vaccines [J].Adv Vet Med,1999.41:419-28.
[119]HAESEBROUCK, F., F. PASMANS, K. CHIERS, et al., Efficacy of vaccinesagainst bacterial diseases in swine: what can we expect?[J]. Vet Microbiol,2004.100:255-68.
[120]VAN OVERBEKE, I., K. CHIERS, E. DONNE, et al., Effect of endobronchialchallenge with Actinobacillus pleuropneumoniae serotype10of pigs vaccinated withbacterins consisting of A. pleuropneumoniae serotype10grown under NAD-rich andNAD-restricted conditions [J]. J Vet Med B Infect Dis Vet Public Health,2003.50:289-93.
[121]JOLIE, R.A., M.H. MULKS, and B.J. THACKER, Cross-protection experimentsin pigs vaccinated with Actinobacillus pleuropneumoniae subtypes1A and1B [J]. VetMicrobiol,1995.45:383-91.
[122]FURESZ, S.E., B.A. MALLARD, J.T. BOSSE, et al., Antibody-andcell-mediated immune responses of Actinobacillus pleuropneumoniae-infected andbacterin-vaccinated pigs [J]. Infect Immun,1997.65:358-65.
[123]HAGA, Y., S. OGINO, S. OHASHI, et al., Protective efficacy of anaffinity-purified hemolysin vaccine against experimental swine pleuropneumonia [J].J Vet Med Sci,1997.59:115-20.
[124]SEAH, J.N., J. FREY, and J. KWANG, The N-terminal domain of RTX toxinApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice [J].Infect Immun,2002.70:6464-7.
[125]HIGGINS, R., S. LARIVIERE, K.R. MITTAL, et al., Evaluation of a KilledVaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae [J].Can Vet J,1985.26:86-89.
[126]THACKER, B. and M. MULKS, Evaluation of commercial Haemophiluspleuropneumoniae vaccine, in Proceedings of International Pig Veterinary SocietyCongress1988.87.
[127]FENWICK, B. and S. HENRY, Porcine pleuropneumonia [J]. J Am Vet MedAssoc,1994.204:1334-40.
[128]APPLEYARD, G.D., S.E. FURESZ, and B.N. WILKIE, Blood lymphocytesubsets in pigs vaccinated and challenged with Actinobacillus pleuropneumoniae [J].Vet Immunol Immunopathol,2002.86:221-8.
[129]WITTE, A., G. WANNER, U. BLASI, et al., Endogenous transmembrane tunnelformation mediated by phi X174lysis protein E [J]. J Bacteriol,1990.172:4109-14.
[130]WITTE, A., G. WANNER, M. SULZNER, et al., Dynamics of PhiX174proteinE-mediated lysis of Escherichia coli [J].Arch Microbiol,1992.157:381-8.
[131]FELNEROVA, D., P. KUDELA, J. BIZIK, et al., T cell-specific immuneresponse induced by bacterial ghosts [J]. Med Sci Monit,2004.10: BR362-70.
[132]SZOSTAK, M.P., A. HENSEL, F.O. EKO, et al., Bacterial ghosts: non-livingcandidate vaccines [J]. J Biotechnol,1996.44:161-70.
[133]LUBITZ, W., A. WITTE, F.O. EKO, et al., Extended recombinant bacterialghost system [J]. J Biotechnol,1999.73:261-73.
[134]LUBITZ, W., Bacterial ghosts as carrier and targeting systems [J]. Expert OpinBiol Ther,2001.1:765-71.
[135]JALAVA, K., F.O. EKO, E. RIEDMANN, et al., Bacterial ghosts as carrier andtargeting systems for mucosal antigen delivery [J]. Expert Rev Vaccines,2003.2:45-51.
[136]RIEDMANN, E.M., J.M. KYD, A.W. CRIPPS, et al., Bacterial ghosts asadjuvant particles [J]. Expert Rev Vaccines,2007.6:241-53.
[137]KATINGER, A., W. LUBITZ, M.P. SZOSTAK, et al., Pigs aerogenouslyimmunized with genetically inactivated (ghosts) or irradiated Actinobacilluspleuropneumoniae are protected against a homologous aerosol challenge despitediffering in pulmonary cellular and antibody responses [J]. J Biotechnol,1999.73:251-60.
[138]HENSEL, A., V. HUTER, A. KATINGER, et al., Intramuscular immunizationwith genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype9protects pigs against homologous aerosol challenge and prevents carrier state [J].Vaccine,2000.18:2945-55.
[139]HUTER, V., A. HENSEL, E. BRAND, et al., Improved protection against lungcolonization by Actinobacillus pleuropneumoniae ghosts: characterization of agenetically inactivated vaccine [J]. J Biotechnol,2000.83:161-72.
[140]NIELSEN, R., Haemophilus pleuropneumoniae serotypes--cross protectionexperiments [J]. Nord Vet Med,1984.36:221-34.
[141]GOETHE, R., O.F. GONZALES, T. LINDNER, et al., A novel strategy forprotective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction ofcultures induced by iron restriction [J]. Vaccine,2000.19:966-75.
[142]WILLSON, P.J., A. ROSSI-CAMPOS, and A.A. POTTER, Tissue reaction andimmunity in swine immunized with Actinobacillus pleuropneumoniae vaccines [J].Can J Vet Res,1995.59:299-305.
[143]RIOUX, S., D. DUBREUIL, C. BEGIN, et al., Evaluation of protective efficacyof an Actinobacillus pleuropneumoniae serotype1lipopolysaccharide-proteinconjugate in mice [J]. Comp Immunol Microbiol Infect Dis,1997.20:63-74.
[144]RIOUX, S., C. GIRARD, J.D. DUBREUIL, et al., Evaluation of the protectiveefficacy of Actinobacillus pleuropneumoniae serotype1detoxifiedlipopolysaccharides or O-polysaccharide-protein conjugate in pigs [J]. Res Vet Sci,1998.65:165-7.
[145]SAZE, K., C. KINOSHITA, F. SHIBA, et al., Effect of passive immunizationwith serotype-specific monoclonal antibodies on Actinobacillus pleuropneumoniaeinfection of mice [J]. J Vet Med Sci,1994.56:97-102.
[146]INZANA, T.J., J. MA, T. WORKMAN, et al., Virulence properties andprotective efficacy of the capsular polymer of Haemophilus (Actinobacillus)pleuropneumoniae serotype5[J]. Infect Immun,1988.56:1880-9.
[147]BYRD, W. and A.M. HOOKE, Immunization with temperature-sensitivemutants of Actinobacillus pleuropneumoniae induces protectivehemolysin-neutralizing antibodies in mice [J]. Curr Microbiol,1997.34:149-54.
[148]RAPP, V.J., R.S. MUNSON, JR., and R.F. ROSS, Outer membrane proteinprofiles of Haemophilus pleuropneumoniae [J]. Infect Immun,1986.52:414-20.
[149]GONZALEZ, G.C., D.L. CAAMANO, and A.B. SCHRYVERS, Identificationand characterization of a porcine-specific transferrin receptor in Actinobacilluspleuropneumoniae [J]. Mol Microbiol,1990.4:1173-9.
[150]GERLACH, G.F., S. KLASHINSKY, C. ANDERSON, et al., Characterization oftwo genes encoding distinct transferrin-binding proteins in different Actinobacilluspleuropneumoniae isolates [J]. Infect Immun,1992.60:3253-61.
[151]DENEER, H.G. and A.A. POTTER, Identification of a maltose-inducible majorouter membrane protein in Actinobacillus (Haemophilus) pleuropneumoniae [J].Microb Pathog,1989.6:425-32.
[152]FREY, J., P. KUHNERT, L. VILLIGER, et al., Cloning and characterization ofan Actinobacillus pleuropneumoniae outer membrane protein belonging to the familyof PALlipoproteins [J]. Res Microbiol,1996.147:351-61.
[153]GERLACH, G.F., C. ANDERSON, S. KLASHINSKY, et al., Molecularcharacterization of a protective outer membrane lipoprotein (OmlA) fromActinobacillus pleuropneumoniae serotype1[J]. Infect Immun,1993.61:565-72.
[154]HODGETTS, A., J.T. BOSSE, J.S. KROLL, et al., Analysis of differentialprotein expression in Actinobacillus pleuropneumoniae by Surface Enhanced LaserDesorption Ionisation--ProteinChip (SELDI) technology [J]. Vet Microbiol,2004.99:215-25.
[155]MAAS, A., J. MEENS, N. BALTES, et al., Development of a DIVA subunitvaccine against Actinobacillus pleuropneumoniae infection [J]. Vaccine,2006.24:7226-37.
[156]CRUZ, W.T., Y.A. NEDIALKOV, B.J. THACKER, et al., Molecularcharacterization of a common48-kilodalton outer membrane protein of Actinobacilluspleuropneumoniae [J]. Infect Immun,1996.64:83-90.
[157]VAN DEN BOSCH, H. and J. FREY, Interference of outer membrane proteinPalA with protective immunity against Actinobacillus pleuropneumoniae infections invaccinated pigs [J]. Vaccine,2003.21:3601-7.
[158]DESLANDES, V., J.H. NASH, J. HAREL, et al., Transcriptional profiling ofActinobacillus pleuropneumoniae under iron-restricted conditions [J]. BMCGenomics,2007.8:72.
[159]GERLACH, G.F., C. ANDERSON, A.A. POTTER, et al., Cloning andexpression of a transferrin-binding protein from Actinobacillus pleuropneumoniae [J].Infect Immun,1992.60:892-8.
[160]ROSSI-CAMPOS, A., C. ANDERSON, G.F. GERLACH, et al., Immunization ofpigs against Actinobacillus pleuropneumoniae with two recombinant proteinpreparations [J]. Vaccine,1992.10:512-8.
[161]VAN OVERBEKE, I., K. CHIERS, R. DUCATELLE, et al., Effect ofendobronchial challenge with Actinobacillus pleuropneumoniae serotype9of pigsvaccinated with a vaccine containing Apx toxins and transferrin-binding proteins [J]. JVet Med B Infect Dis Vet Public Health,2001.48:15-20.
[162]MIKAEL, L.G., R. SRIKUMAR, J.W. COULTON, et al., fhuAof Actinobacilluspleuropneumoniae encodes a ferrichrome receptor but is not regulated by iron [J].Infect Immun,2003.71:2911-5.
[163]MIKAEL, L.G., P.D. PAWELEK, J. LABRIE, et al., Molecular cloning andcharacterization of the ferric hydroxamate uptake (fhu) operon in Actinobacilluspleuropneumoniae [J]. Microbiology,2002.148:2869-82.
[164]SRIKUMAR, R., L.G. MIKAEL, P.D. PAWELEK, et al., Molecular cloning ofhaemoglobin-binding protein HgbA in the outer membrane of Actinobacilluspleuropneumoniae [J]. Microbiology,2004.150:1723-34.
[165]SHAKARJI, L., L.G. MIKAEL, R. SRIKUMAR, et al., Fhua and HgbA, outermembrane proteins of Actinobacillus pleuropneumoniae: their role as virulencedeterminants [J]. Can J Microbiol,2006.52:391-6.
[166]INZANA, T.J., Virulence properties of Actinobacillus pleuropneumoniae [J].Microb Pathog,1991.11:305-16.
[167]CRUIJSEN, T.L., L.A. VAN LEENGOED, T.C. DEKKER-NOOREN, et al.,Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolarmacrophages and polymorphonuclear leukocytes isolated from pigs [J]. Infect Immun,1992.60:4867-71.
[168]JANSEN, R., J. BRIAIRE, A.B. VAN GEEL, et al., Genetic map of theActinobacillus pleuropneumoniae RTX-toxin (Apx) operons: characterization of theApxIII operons [J]. Infect Immun,1994.62:4411-8.
[169]FURESZ, S.E., B.N. WILKIE, B.A. MALLARD, et al., Anti-haemolysin IgG1to IgG2ratios correlate with haemolysin neutralization titres and lung lesion scores inActinobacillus pleuropneumoniae infected pigs [J]. Vaccine,1998.16:1971-5.
[170]SEAH, J.N. and J. KWANG, Localization of linear cytotoxic and pro-apoptoticepitopes in RTX toxin ApxIII of Actinobacillus pleuropneumoniae [J]. Vaccine,2004.22:1494-7.
[171]BYRD, W. and S. KADIS, Preparation, characterization, and immunogenicity ofconjugate vaccines directed against Actinobacillus pleuropneumoniae virulencedeterminants [J]. Infect Immun,1992.60:3042-51.
[172]FREY, J., H. VAN DEN BOSCH, R. SEGERS, et al., Identification of a secondhemolysin (HlyII) in Actinobacillus pleuropneumoniae serotype1and expression ofthe gene in Escherichia coli [J]. Infect Immun,1992.60:1671-6.
[173]BEAUDET, R., G. MCSWEEN, G. BOULAY, et al., Protection of mice andswine against infection with Actinobacillus pleuropneumoniae by vaccination [J]. VetMicrobiol,1994.39:71-81.
[174]FREY, J., Exotoxins of Actinobacillus pleuropneumonia [J]. Haemophilus,Actinobacillus, and Pasteurella,1995.
[175]MADSEN, M.E., K.G. CARNAHAN, and R.N. THWAITS, Evaluation of piglungs following an experimental challenge with Actinobacillus pleuropneumoniaeserotype1and5in pigs inoculated with either hemolysin protein and/or outermembrane proteins [J]. FEMS Microbiol Lett,1995.131:329-35.
[176]CHIERS, K., I. VAN OVERBEKE, P. DE LAENDER, et al., Effects ofendobronchial challenge with Actinobacillus pleuropneumoniae serotype9of pigsvaccinated with inactivated vaccines containing the Apx toxins [J]. Vet Q,1998.20:65-9.
[177]TUMAMAO, J.Q., R.E. BOWLES, H. VAN DEN BOSCH, et al., Comparisonof the efficacy of a subunit and a live streptomycin-dependent porcinepleuropneumonia vaccine [J].Aust Vet J,2004.82:370-4.
[178]MEEUSEN, E.N., J. WALKER, A. PETERS, et al., Current status of veterinaryvaccines [J]. Clin Microbiol Rev,2007.20:489-510, table of contents.
[179]MOSIER, D., J. IANDOLO, D. ROGERS, et al., Characterization of a54-kDaheat-shock-inducible protein of Pasteurella haemolytica [J]. Vet Microbiol,1998.60:67-73.
[180]THOMAS, L.D., M.L. DUNKLEY, R. MOORE, et al., Catalase immunizationfrom Pseudomonas aeruginosa enhances bacterial clearance in the rat lung [J].Vaccine,2000.19:348-57.
[181]WILLSON, P.J., G.F. GERLACH, S. KLASHINSKY, et al., Cloning andcharacterization of the gene coding for NADPH-sulfite reductase hemoprotein fromActinobacillus pleuropneumoniae and use of the protein product as a vaccine [J]. CanJ Vet Res,2001.65:206-12.
[182]SCHALLER, A., R. KUHN, P. KUHNERT, et al., Characterization of apxIVA, anew RTX determinant of Actinobacillus pleuropneumoniae [J]. Microbiology,1999.145(Pt8):2105-16.
[183]HAESEBROUK, F., A. VAN DE KERKHOF, P. DOM, et al., Cross-protectionbetween Actinobacillus pleuropneumoniae biotypes-serotypes in pigs [J]. VetMicrobiol,1996.52:277-84.
[184]FULLER, T.E., B.J. THACKER, and M.H. MULKS, A riboflavin auxotroph ofActinobacillus pleuropneumoniae is attenuated in swine [J]. Infect Immun,1996.64:4659-64.
[185]INGHAM, A., Y. ZHANG, and C. PRIDEAUX, Attenuation of Actinobacilluspleuropneumoniae by inactivation of aroQ [J]. Vet Microbiol,2002.84:263-73.
[186]GARSIDE, L.H., M. COLLINS, P.R. LANGFORD, et al., Actinobacilluspleuropneumoniae serotype1carrying the defined aroA mutation is fully avirulent inthe pig [J]. Res Vet Sci,2002.72:163-7.
[187]BALTES, N., I. HENNIG-PAUKA, I. JACOBSEN, et al., Identification ofdimethyl sulfoxide reductase in Actinobacillus pleuropneumoniae and its role ininfection [J]. Infect Immun,2003.71:6784-92.
[188]SHEEHAN, B.J., P.R. LANGFORD, A.N. RYCROFT, et al.,
[Cu,Zn]-Superoxide dismutase mutants of the swine pathogen Actinobacilluspleuropneumoniae are unattenuated in infections of the natural host [J]. Infect Immun,2000.68:4778-81.
[189]BALTES, N., W. TONPITAK, G.F. GERLACH, et al., Actinobacilluspleuropneumoniae iron transport and urease activity: effects on bacterial virulenceand host immune response [J]. Infect Immun,2001.69:472-8.
[190]BOSSE, J.T., R.P. JOHNSON, M. NEMEC, et al., Protective local and systemicantibody responses of swine exposed to an aerosol of Actinobacilluspleuropneumoniae serotype1[J]. Infect Immun,1992.60:479-84.
[191]XU, F., X. CHEN, A. SHI, et al., Characterization and immunogenicity of anapxIA mutant of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2006.118:230-9.
[192]PRIDEAUX, C.T., L. PIERCE, J. KRYWULT, et al., Protection of mice againstchallenge with homologous and heterologous serovars of Actinobacilluspleuropneumoniae after live vaccination [J]. Curr Microbiol,1998.37:324-32.
[193]PRIDEAUX, C.T., C. LENGHAUS, J. KRYWULT, et al., Vaccination andprotection of pigs against pleuropneumonia with a vaccine strain of Actinobacilluspleuropneumoniae produced by site-specific mutagenesis of the ApxII operon [J].Infect Immun,1999.67:1962-6.
[194]INZANA, T.J., G. GLINDEMANN, B. FENWICK, et al., Risk assessment oftransmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae [J].Vet Microbiol,2004.104:63-71.
[195]BEI, W., Q. HE, R. ZHOU, et al., Evaluation of immunogenicity and protectiveefficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drugresistance marker in the pigs [J]. Vet Microbiol,2007.125:120-7.
[196]BEI, W., Q. HE, L. YAN, et al., Construction and characterization of a live,attenuated apxIICAinactivation mutant of Actinobacillus pleuropneumoniae lacking adrug resistance marker [J]. FEMS Microbiol Lett,2005.243:21-7.
[197]LIN, L., W. BEI, Y. SHA, et al., Construction and immunogencity of aDeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar1[J]. FEMS Microbiol Lett,2007.274:55-62.
[198]INZANA, T.J., J. TODD, and H.P. VEIT, Safety, stability, and efficacy ofnoncapsulated mutants of Actinobacillus pleuropneumoniae for use in live vaccines[J]. Infect Immun,1993.61:1682-6.
[199]TONPITAK, W., N. BALTES, I. HENNIG-PAUKA, et al., Construction of anActinobacillus pleuropneumoniae serotype2prototype live negative-marker vaccine[J]. Infect Immun,2002.70:7120-5.
[200]MAAS, A., I.D. JACOBSEN, J. MEENS, et al., Use of an Actinobacilluspleuropneumoniae multiple mutant as a vaccine that allows differentiation ofvaccinated and infected animals [J]. Infect Immun,2006.74:4124-32.
[201]BOSSE, J.T., H. JANSON, B.J. SHEEHAN, et al., Actinobacilluspleuropneumoniae: pathobiology and pathogenesis of infection [J]. Microbes Infect,2002.4:225-35.
[202]JACQUES, M., M. BELANGER, G. ROY, et al., Adherence of Actinobacilluspleuropneumoniae to porcine tracheal epithelial cells and frozen lung sections [J]. VetMicrobiol,1991.27:133-43.
[203]DOM, P., F. HAESEBROUCK, R. DUCATELLE, et al., In vivo association ofActinobacillus pleuropneumoniae serotype2with the respiratory epithelium of pigs[J]. Infect Immun,1994.62:1262-7.
[204]ABUL-MILH, M., S.E. PARADIS, J.D. DUBREUIL, et al., Binding ofActinobacillus pleuropneumoniae lipopolysaccharides to glycosphingolipidsevaluated by thin-layer chromatography [J]. Infect Immun,1999.67:4983-7.
[205]MORA, J.R., M.R. BONO, N. MANJUNATH, et al., Selective imprinting ofgut-homing T cells by Peyer's patch dendritic cells [J]. Nature,2003.424:88-93.
[206]KUNKEL, E.J. and E.C. BUTCHER, Plasma-cell homing [J]. Nat Rev Immunol,2003.3:822-9.
[207]PILETTE, C., Y. OUADRHIRI, V. GODDING, et al., Lung mucosal immunity:immunoglobulin-Arevisited [J]. Eur Respir J,2001.18:571-88.
[208]WOOF, J.M. and M.A. KERR, The function of immunoglobulin A in immunity[J]. J Pathol,2006.208:270-82.
[209]NEUTRA, M.R. and P.A. KOZLOWSKI, Mucosal vaccines: the promise and thechallenge [J]. Nat Rev Immunol,2006.6:148-58.
[210]GERDTS, V., G.K. MUTWIRI, S.K. TIKOO, et al., Mucosal delivery ofvaccines in domestic animals [J]. Vet Res,2006.37:487-510.
[211]PABST, R. and R.M. BINNS, The immune system of the respiratory tract in pigs[J]. Vet Immunol Immunopathol,1994.43:151-6.
[212]BOUVET, J.P., N. DECROIX, and P. PAMONSINLAPATHAM, Stimulation oflocal antibody production: parenteral or mucosal vaccination?[J]. Trends Immunol,2002.23:209-13.
[213]LIAO, C.W., I.C. CHENG, K.S. YEH, et al., Release characteristics ofmicrospheres prepared by co-spray drying Actinobacillus pleuropneumoniae antigensand aqueous ethyl-cellulose dispersion [J]. J Microencapsul,2001.18:285-97.
[214]RYAN, E.J., L.M. DALY, and K.H. MILLS, Immunomodulators and deliverysystems for vaccination by mucosal routes [J]. Trends Biotechnol,2001.19:293-304.
[215]SHIN, S.J., J.L. BAE, Y.W. CHO, et al., Induction of antigen-specific immuneresponses by oral vaccination with Saccharomyces cerevisiae expressingActinobacillus pleuropneumoniae ApxIIA [J]. FEMS Immunol Med Microbiol,2005.43:155-64.
[216]LEE, K.Y., D.H. KIM, T.J. KANG, et al., Induction of protective immuneresponses against the challenge of Actinobacillus pleuropneumoniae by the oraladministration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria[J]. FEMS Immunol Med Microbiol,2006.48:381-9.
[217]LIAO, C.W., H.Y. CHIOU, K.S. YEH, et al., Oral immunization usingformalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped inmicrospheres with aqueous dispersion polymers prepared using a co-spray dryingprocess [J]. Prev Vet Med,2003.61:1-15.
[218]SOSROSENO, W., A review of the mechanisms of oral tolerance andimmunotherapy [J]. J R Soc Med,1995.88:14-7.
[219]TAKAHASHI, I., M. MARINARO, H. KIYONO, et al., Mechanisms formucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin [J]. JInfect Dis,1996.173:627-35.
[220]RAPPUOLI, R., M. PIZZA, G. DOUCE, et al., Structure and mucosaladjuvanticity of cholera and Escherichia coli heat-labile enterotoxins [J]. ImmunolToday,1999.20:493-500.
[221]MCCLUSKIE, M.J. and H.L. DAVIS, CpG DNA as mucosal adjuvant [J].Vaccine,1999.18:231-7.
[222]KRIEG, A.M., Immune effects and mechanisms of action of CpG motifs [J].Vaccine,2000.19:618-22.
[223]RANKIN, R., R. PONTAROLLO, X. IOANNOU, et al., CpG motifidentification for veterinary and laboratory species demonstrates that sequencerecognition is highly conserved [J]. Antisense Nucleic Acid Drug Dev,2001.11:333-40.
[224]ALCON, V., M. BACA-ESTRADA, M. VEGA-LOPEZ, et al., Mucosal deliveryof bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles inpigs [J].AAPS J,2005.7: E566-71.
[225]ALCON, V.L., M. FOLDVARI, M. SNIDER, et al., Induction of protectiveimmunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in alipid-based delivery system (Biphasix)[J]. Vaccine,2003.21:1811-4.
[226]KIM, T.J., K.H. KIM, and J.I. LEE, Stimulation of mucosal and systemicantibody responses against recombinant transferrin-binding protein B ofActinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets[J]. J Vet Med Sci,2007.69:535-9.
[227]SLAUCH, J.M., M.J. MAHAN, and J.J. MEKALANOS, In vivo expressiontechnology for selection of bacterial genes specifically induced in host tissues [J].Methods Enzymol,1994.235:481-92.
[228]FULLER, T.E., R.J. SHEA, B.J. THACKER, et al., Identification of in vivoinduced genes in Actinobacillus pleuropneumoniae [J]. Microb Pathog,1999.27:311-27.
[229]SHEA, R.J. and M.H. MULKS, ohr, Encoding an organic hydroperoxidereductase, is an in vivo-induced gene in Actinobacillus pleuropneumoniae [J]. InfectImmun,2002.70:794-802.
[230]WANG, J., A. MUSHEGIAN, S. LORY, et al., Large-scale isolation of candidatevirulence genes of Pseudomonas aeruginosa by in vivo selection [J]. Proc Natl AcadSci U SA,1996.93:10434-9.
[231]FULLER, T.E., M.J. KENNEDY, and D.E. LOWERY, Identification ofPasteurella multocida virulence genes in a septicemic mouse model usingsignature-tagged mutagenesis [J]. Microb Pathog,2000.29:25-38.
[232]WAGNER, T.K. and M.H. MULKS, A subset of Actinobacilluspleuropneumoniae in vivo induced promoters respond to branched-chain amino acidlimitation [J]. FEMS Immunol Med Microbiol,2006.48:192-204.
[233]WAGNER, T.K. and M.H. MULKS, Identification of the Actinobacilluspleuropneumoniae leucine-responsive regulatory protein and its involvement in theregulation of in vivo-induced genes [J]. Infect Immun,2007.75:91-103.
[234]FULLER, T.E., B.J. THACKER, C.O. DURAN, et al., A genetically-definedriboflavin auxotroph of Actinobacillus pleuropneumoniae as a live attenuated vaccine[J]. Vaccine,2000.18:2867-77.
[235]FULLER, T.E., S. MARTIN, J.F. TEEL, et al., Identification of Actinobacilluspleuropneumoniae virulence genes using signature-tagged mutagenesis in a swineinfection model [J]. Microb Pathog,2000.29:39-51.
[236]SHEEHAN, B.J., J.T. BOSSE, A.J. BEDDEK, et al., Identification ofActinobacillus pleuropneumoniae genes important for survival during infection in itsnatural host [J]. Infect Immun,2003.71:3960-70.
[237]MARONCLE, N., D. BALESTRINO, C. RICH, et al., Identification ofKlebsiella pneumoniae genes involved in intestinal colonization and adhesion usingsignature-tagged mutagenesis [J]. Infect Immun,2002.70:4729-34.
[238]BEDDEK, A.J., B.J. SHEEHAN, J.T. BOSSE, et al., Two TonB systems inActinobacillus pleuropneumoniae: their roles in iron acquisition and virulence [J].Infect Immun,2004.72:701-8.
[239]TONPITAK, W., S. THIEDE, W. OSWALD, et al., Actinobacilluspleuropneumoniae iron transport: a set of exbBD genes is transcriptionally linked tothe tbpB gene and required for utilization of transferrin-bound iron [J]. Infect Immun,2000.68:1164-70.
[240]GRAHAM, J.E. and J.E. CLARK-CURTISS, Identification of Mycobacteriumtuberculosis RNAs synthesized in response to phagocytosis by human macrophagesby selective capture of transcribed sequences (SCOTS)[J]. Proc Natl Acad Sci U S A,1999.96:11554-9.
[241]BALTES, N. and G.F. GERLACH, Identification of genes transcribed byActinobacillus pleuropneumoniae in necrotic porcine lung tissue by using selectivecapture of transcribed sequences [J]. Infect Immun,2004.72:6711-6.
[242]ST GEME, J.W.,3RD, D. CUTTER, and S.J. BARENKAMP, Characterizationof the genetic locus encoding Haemophilus influenzae type b surface fibrils [J]. JBacteriol,1996.178:6281-7.
[243]COTTER, S.E., H.J. YEO, T. JUEHNE, et al., Architecture and adhesive activityof the Haemophilus influenzae Hsf adhesin [J]. J Bacteriol,2005.187:4656-64.
[244]GREEN, J., A.D. SHARROCKS, J.I. MACINNES, et al., Purification of HlyX,a potential regulator of haemolysin synthesis, and properties of HlyX:FNR hybrids [J].Proc Biol Sci,1992.248:79-84.
[245]MISTRY, D. and R.A. STOCKLEY, IgA1protease [J]. Int J Biochem Cell Biol,2006.38:1244-8.
[246]RIESBECK, K. and T. NORDSTROM, Structure and immunological action ofthe human pathogen Moraxella catarrhalis IgD-binding protein [J]. Crit Rev Immunol,2006.26:353-76.
[247]MORA, M., D. VEGGI, L. SANTINI, et al., Reverse vaccinology [J]. DrugDiscov Today,2003.8:459-64.
[248]SERRUTO, D. and R. RAPPUOLI, Post-genomic vaccine development [J].FEBS Lett,2006.580:2985-92.
[249]PIZZA, M., V. SCARLATO, V. MASIGNANI, et al., Identification of vaccinecandidates against serogroup B meningococcus by whole-genome sequencing [J].Science,2000.287:1816-20.
[250]CHUNG, J.W., C. NG-THOW-HING, L.I. BUDMAN, et al., Outer membraneproteome of Actinobacillus pleuropneumoniae: LC-MS/MS analyses validate in silicopredictions [J]. Proteomics,2007.7:1854-65.
[251]GRIFANTINI, R., E. BARTOLINI, A. MUZZI, et al., Previously unrecognizedvaccine candidates against group B meningococcus identified by DNAmicroarrays [J].Nat Biotechnol,2002.20:914-21.
[252]BELANGER, M., D. DUBREUIL, J. HAREL, et al., Role oflipopolysaccharides in adherence of Actinobacillus pleuropneumoniae to porcinetracheal rings [J]. Infect Immun,1990.58:3523-30.
[253]PARADIS, S.E., D. DUBREUIL, S. RIOUX, et al., High-molecular-masslipopolysaccharides are involved in Actinobacillus pleuropneumoniae adherence toporcine respiratory tract cells [J]. Infect Immun,1994.62:3311-9.
[254]PARADIS, S.E., J.D. DUBREUIL, M. GOTTSCHALK, et al., Inhibition ofadherence of Actinobacillus pleuropneumoniae to porcine respiratory tract cells bymonoclonal antibodies directed against LPS and partial characterization of the LPSreceptors [J]. Curr Microbiol,1999.39:313-0320.
[255]MAGNUSSON, U., J. BOSSE, B.A. MALLARD, et al., Antibody response toActinobacillus pleuropneumoniae antigens after vaccination of pigs bred for high andlow immune response [J]. Vaccine,1997.15:997-1000.
[256]SHIN, N.R., I.S. CHOI, J.M. KIM, et al., Effective methods for the productionof immunoglobulin Y using immunogens of Bordetella bronchiseptica, Pasteurellamultocida andActinobacillus pleuropneumoniae [J]. J Vet Sci,2002.3:47-57.
[257]RAMJEET, M., V. DESLANDES, J. GOURE, et al., Actinobacilluspleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies[J].Anim Health Res Rev,2008.9:25-45.
[258]THIBOUTOT, D.M., Overview of acne and its treatment [J]. Cutis,2008.81:3-7.
[259]MIYATA, H., K. NOMOTO, and K. TAKEYA, Characteristics of resistance toListeria monocytogenes enhanced by Corynebacterium parvum in mice [J].Immunology,1980.40:33-9.
[260]KIRCHNER, H., H.M. HIRT, and K. MUNK, Protection against herpes simplexvirus infection in mice by Corynebacterium parvum [J]. Infect Immun,1977.16:9-11.
[261]ABEL, L.C., S. CHEN, L.G. RICCA, et al., Adjuvant effect of LPS and killedPropionibacterium acnes on the development of experimental gastrointestinalnematode infestation in sheep [J]. Parasite Immunol,2009.31:604-12.
[262]YANG, P., L.C. LEI, F. XIE, et al., Immune activity of Propionibacterium acnesagainst Actinobacillus pleuropneumoniae infection in mice, in Chinese Journal ofPreventive Veterinary Medicine2009.596-9.
[263]李林溪,雷连成,高宇,等,痤疮丙酸杆菌对小鼠抗胸膜肺炎放线杆菌血清7型9型的免疫保护[J].河北科技师范学院学报,2010.24:4.
[264]MCDOWELL, A., S. VALANNE, G. RAMAGE, et al., Propionibacterium acnestypes I and II represent phylogenetically distinct groups [J]. J Clin Microbiol,2005.43:326-34.
[265]MURRAY, M.G. and W.F. THOMPSON, Rapid isolation of high molecularweight plant DNA[J]. NucleicAcids Res,1980.8:4321-5.
[266]ZHANG, Y., I-TASSER server for protein3D structure prediction [J]. BMCBioinformatics,2008.9:40.
[267]SHEN, H.B. and K.C. CHOU, Gpos-PLoc: an ensemble classifier for predictingsubcellular localization of Gram-positive bacterial proteins [J]. Protein Eng Des Sel,2007.20:39-46.
[268]NASCIMENTO, E., J.O. COSTA, M.P. GUIMARAES, et al., Effective immuneprotection of pigs against cysticercosis [J]. Vet Immunol Immunopathol,1995.45:127-37.
[269]VILELA MDE, C., D.C. GOMES, A. MARQUES-DA-SILVA EDE, et al.,Successful vaccination against Leishmania chagasi infection in BALB/c mice withfreeze-thawed Leishmania antigen and Corynebacterium parvum [J]. Acta Trop,2007.104:133-9.
[270]LYONS, J.A., D.A. BEMIS, M.J. BRYANT, et al., Isolation ofPropionibacterium acnes from a case of placentitis and abortion in a cow [J]. J VetDiagn Invest,2009.21:274-7.
[271]SALANITRO, J.P., I.G. BLAKE, and P.A. MUIRHEAD, Isolation andidentification of fecal bacteria from adult swine [J]. Appl Environ Microbiol,1977.33:79-84.
[272]SQUAIELLA, C.C., A.L. LONGHINI, E.G. BRAGA, et al., Modulation of thetype I hypersensitivity late phase reaction to OVA by Propionibacterium acnes-solublepolysaccharide [J]. Immunol Lett,2008.121:157-66.
[273]WU, L., Structure and functional characterization of single-strand DNA bindingprotein SSDP1: carboxyl-terminal of SSDP1has transcription activity [J]. BiochemBiophys Res Commun,2006.339:977-84.
[274]SHIBUSAWA, Y., Y. INO, T. KINEBUCHI, et al., Purification of single-strandDNA binding protein from an Escherichia coli lysate using counter-currentchromatography, partition and precipitation [J]. J Chromatogr B Analyt TechnolBiomed Life Sci,2003.793:275-9.
[275]CHOU, K.C. and H.B. SHEN, Cell-PLoc: a package of Web servers forpredicting subcellular localization of proteins in various organisms [J]. Nat Protoc,2008.3:153-62.
[276]YUAN, F., J. LIU, Y. GUO, et al., Influences of ORF1on the virulence andimmunogenicity of Actinobacillus pleuropneumoniae [J]. Curr Microbiol,2011.63:574-80.
[277]TURNI, C. and P.J. BLACKALL, An evaluation of the apxIVA based PCR-REAmethod for differentiation of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2007.121:163-9.
[278]WANG, C., Y. WANG, M. SHAO, et al., Positive role for rApxIVN in theimmune protection of pigs against infection by Actinobacillus pleuropneumoniae [J].Vaccine,2009.27:5816-21.
[279]LIU, J., X. CHEN, L. LIN, et al., Potential use an Actinobacilluspleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine thatallows serological differentiation between vaccinated and infected animals [J].Vaccine,2007.25:7696-705.
[280]马三梅,王永飞,绿色荧光蛋白和荧光素酶[J].生物学教学,2005.30:5-6.
[281]GREER, L.F.,3RD and A.A. SZALAY, Imaging of light emission from theexpression of luciferases in living cells and organisms: a review [J]. Luminescence,2002.17:43-74.
[282]杜彦艳,单保恩,报告基因荧光素酶在科研中的应用[J].中华肿瘤防治杂志,2009.16:715-718.
[283]WAIDMANN, M.S., F.S. BLEICHRODT, T. LASLO, et al., Bacterial luciferasereporters: the Swiss army knife of molecular biology [J]. Bioeng Bugs,2011.2:8-16.
[284]HALL, M.P., J. UNCH, B.F. BINKOWSKI, et al., Engineered luciferase reporterfrom a deep sea shrimp utilizing a novel imidazopyrazinone substrate [J]. ACS ChemBiol,2012.7:1848-57.
[285]STAFF, T.S. Top10Innovations2012. The Scientist’s5th installment of itsannual competition attracted submissions from across the life science spectrum.2012.
[286]SONG, G., Q. JIANG, T. XU, et al., A convenient luminescence assay offerroportin internalization to study its interaction with hepcidin [J]. FEBS J,2013.280:1773-81.
[287]BOEKEMA, B.K., J.P. VAN PUTTEN, N. STOCKHOFE-ZURWIEDEN, et al.,Host cell contact-induced transcription of the type IV fimbria gene cluster ofActinobacillus pleuropneumoniae [J]. Infect Immun,2004.72:691-700.
[288]BOSSE, J.T., A.L. DURHAM, A.N. RYCROFT, et al., New plasmid tools forgenetic analysis of Actinobacillus pleuropneumoniae and other pasteurellaceae [J].Appl Environ Microbiol,2009.75:6124-31.
[289]LANGFORD, P.R., B.M. LOYNDS, and J.S. KROLL, Cloning and molecularcharacterization of Cu,Zn superoxide dismutase from Actinobacilluspleuropneumoniae [J]. Infect Immun,1996.64:5035-41.
[290]BOSSE, J.T., J.H. NASH, J.S. KROLL, et al., Harnessing natural transformationin Actinobacillus pleuropneumoniae: a simple method for allelic replacements [J].FEMS Microbiol Lett,2004.233:277-81.
[291]WIDDER, E.A., Bioluminescence in the ocean: origins of biological, chemical,and ecological diversity [J]. Science,2010.328:704-8.
[292]MELNICK, J.S., J. JANES, S. KIM, et al., An efficient rapid system forprofiling the cellular activities of molecular libraries [J]. Proc Natl Acad Sci U S A,2006.103:3153-8.
[293]DOSHI, U. and A.P. LI, Luciferin IPA-based higher throughput humanhepatocyte screening assays for CYP3A4inhibition and induction [J]. J BiomolScreen,2011.16:903-9.
[294]SMIRNOVA, N.A., R.E. HASKEW-LAYTON, M. BASSO, et al., Developmentof Neh2-luciferase reporter and its application for high throughput screening andreal-time monitoring of Nrf2activators [J]. Chem Biol,2011.18:752-65.
[295]PERROY, J., S. PONTIER, P.G. CHAREST, et al., Real-time monitoring ofubiquitination in living cells by BRET [J]. Nat Methods,2004.1:203-8.
[296]REMY, I. and S.W. MICHNICK, A highly sensitive protein-protein interactionassay based on Gaussia luciferase [J]. Nat Methods,2006.3:977-9.
[297]TANNOUS, B.A., D.E. KIM, J.L. FERNANDEZ, et al., Codon-optimizedGaussia luciferase cDNA for mammalian gene expression in culture and in vivo [J].Mol Ther,2005.11:435-43.
[298]MARKOVA, S.V., S. GOLZ, L.A. FRANK, et al., Cloning and expression ofcDNA for a luciferase from the marine copepod Metridia longa. A novel secretedbioluminescent reporter enzyme [J]. J Biol Chem,2004.279:3212-7.
[299]NAKAJIMA, Y., K. KOBAYASHI, K. YAMAGISHI, et al., cDNA cloning andcharacterization of a secreted luciferase from the luminous Japanese ostracod,Cypridina noctiluca [J]. Biosci Biotechnol Biochem,2004.68:565-70.
[300]SUZUKI, C., Y. NAKAJIMA, H. AKIMOTO, et al., A new additional reporterenzyme, dinoflagellate luciferase, for monitoring of gene expression in mammaliancells [J]. Gene,2005.344:61-6.
[301]INOUYE, S., K. WATANABE, H. NAKAMURA, et al., Secretional luciferaseof the luminous shrimp Oplophorus gracilirostris: cDNA cloning of a novelimidazopyrazinone luciferase(1)[J]. FEBS Lett,2000.481:19-25.
[302]WURDINGER, T., C. BADR, L. PIKE, et al., A secreted luciferase for ex vivomonitoring of in vivo processes [J]. Nat Methods,2008.5:171-3.
[303]ANDREU, N., A. ZELMER, T. FLETCHER, et al., Optimisation ofbioluminescent reporters for use with mycobacteria [J]. PLoS One,2010.5: e10777.
[304]SHIMOMURA, O., T. MASUGI, F.H. JOHNSON, et al., Properties and reactionmechanism of the bioluminescence system of the deep-sea shrimp Oplophorusgracilorostris [J]. Biochemistry,1978.17:994-8.
[305]SONG, G., Q. JIANG, T. XU, et al., A convenient luminescence assay offerroportin internalization to study its interaction with hepcidin [J]. FEBS J,2013.
[306]SLEIGHT, S.C., B.A. BARTLEY, J.A. LIEVIANT, et al., In-Fusion BioBrickassembly and re-engineering [J]. NucleicAcids Res,2010.38:2624-36.
[307]WANG, Y., S.D. GOODMAN, R.J. REDFIELD, et al., Natural transformationand DNA uptake signal sequences in Actinobacillus actinomycetemcomitans [J]. JBacteriol,2002.184:3442-9.
[308]JANSEN, R., J. BRIAIRE, H.E. SMITH, et al., Knockout mutants ofActinobacillus pleuropneumoniae serotype1that are devoid of RTX toxins do notactivate or kill porcine neutrophils [J]. Infect Immun,1995.63:27-37.
[309]WARD, C.K., M.L. LAWRENCE, H.P. VEIT, et al., Cloning and mutagenesis ofa serotype-specific DNA region involved in encapsulation and virulence ofActinobacillus pleuropneumoniae serotype5a: concomitant expression of serotype5aand1capsular polysaccharides in recombinant A. pleuropneumoniae serotype1[J].Infect Immun,1998.66:3326-36.
[310]OSWALD, W., W. TONPITAK, G. OHRT, et al., A single-step transconjugationsystem for the introduction of unmarked deletions into Actinobacilluspleuropneumoniae serotype7using a sucrose sensitivity marker [J]. FEMS MicrobiolLett,1999.179:153-60.
[311]LIU, J., X. CHEN, C. TAN, et al., In vivo induced RTX toxin ApxIVA isessential for the full virulence of Actinobacillus pleuropneumoniae [J]. Vet Microbiol,2009.137:282-9.
[312]EAMENS, G.J., J.R. GONSALVES, A.M. WHITTINGTON, et al., Evaluationof serovar-independent ELISA antigens of Actinobacillus pleuropneumoniae in pigs,following experimental challenge with A. pleuropneumoniae, Mycoplasmahyopneumoniae and Pasteurella multocida [J].Aust Vet J,2012.90:225-34.
[313]CHO, W.S., C. CHOI, and C. CHAE, In situ hybridization for the detection ofthe apxIV gene in the lungs of pigs experimentally infected with twelveActinobacillus pleuropneumoniae serotypes [J]. Vet Res,2002.33:653-60.
[314]HU, D., H. HAN, R. ZHOU, et al., Gold(III) enhanced chemiluminescenceimmunoassay for detection of antibody against ApxIV of Actinobacilluspleuropneumoniae [J].Analyst,2008.133:768-73.
[315]TOBIAS, T.J., A. BOUMA, D. KLINKENBERG, et al., Detection ofActinobacillus pleuropneumoniae in pigs by real-time quantitative PCR for theapxIVAgene [J]. Vet J,2012.193:557-60.
[316]FERRIERES, L., G. HEMERY, T. NHAM, et al., Silent mischief: bacteriophageMu insertions contaminate products of Escherichia coli random mutagenesisperformed using suicidal transposon delivery plasmids mobilized by broad-host-rangeRP4conjugative machinery [J]. J Bacteriol,2010.192:6418-27.
[317]GORYSHIN, I.Y., J. JENDRISAK, L.M. HOFFMAN, et al., Insertionaltransposon mutagenesis by electroporation of released Tn5transposition complexes[J]. Nat Biotechnol,2000.18:97-100.
[318]HAYES, F., Transposon-based strategies for microbial functional genomics andproteomics [J].Annu Rev Genet,2003.37:3-29.
[319]HOFFMAN, L.M., J.J. JENDRISAK, R.J. MEIS, et al., Transposome insertionalmutagenesis and direct sequencing of microbial genomes [J]. Genetica,2000.108:19-24.
[320]CHIANG, S.L. and E.J. RUBIN, Construction of a mariner-based transposon forepitope-tagging and genomic targeting [J]. Gene,2002.296:179-85.
[321]MILLER, V.L. and J.J. MEKALANOS, A novel suicide vector and its use inconstruction of insertion mutations: osmoregulation of outer membrane proteins andvirulence determinants in Vibrio cholerae requires toxR [J]. J Bacteriol,1988.170:2575-83.
[322]SERINA, S., F. NOZZA, G. NICASTRO, et al., Scanning the Escherichia colichromosome by random transposon mutagenesis and multiple phenotypic screening[J]. Res Microbiol,2004.155:692-701.
[323]THOMAS, C.M. and C.A. SMITH, Incompatibility group P plasmids: genetics,evolution, and use in genetic manipulation [J]. Annu Rev Microbiol,1987.41:77-101.
[324]FIGURSKI, D.H. and D.R. HELINSKI, Replication of an origin-containingderivative of plasmid RK2dependent on a plasmid function provided in trans [J]. ProcNatlAcad Sci U SA,1979.76:1648-52.
[325]GROISMAN, E.A., In vivo genetic engineering with bacteriophage Mu [J].Methods Enzymol,1991.204:180-212.
[326]SIMON, R., U. PRIEFER, and A. P HLER, A broad host range mobilizationsystem for in vivo genetic engineering: transposon mutagenesis in Gram negativebacteria [J]. Biotechnology,1983.1:784-791.
[327]DE LORENZO, V. and K.N. TIMMIS, Analysis and construction of stablephenotypes in gram-negative bacteria with Tn5-and Tn10-derived minitransposons[J]. Methods Enzymol,1994.235:386-405.
[328]HUNSTAD, D.A., S.S. JUSTICE, C.S. HUNG, et al., Suppression of bladderepithelial cytokine responses by uropathogenic Escherichia coli [J]. Infect Immun,2005.73:3999-4006.
[329]MOXLEY, R.A., E.M. BERBEROV, D.H. FRANCIS, et al., Pathogenicity of anenterotoxigenic Escherichia coli hemolysin (hlyA) mutant in gnotobiotic piglets [J].Infect Immun,1998.66:5031-5.
[330]LAWLEY, T.D., K. CHAN, L.J. THOMPSON, et al., Genome-wide screen forSalmonella genes required for long-term systemic infection of the mouse [J]. PLoSPathog,2006.2: e11.
[331]POBIGAYLO, N., D. WETTER, S. SZYMCZAK, et al., Construction of a largesignature-tagged mini-Tn5transposon library and its application to mutagenesis ofSinorhizobium meliloti [J].Appl Environ Microbiol,2006.72:4329-37.
[332]ZHANG, X.X. and P.B. RAINEY, Dual involvement of CbrAB and NtrBC in theregulation of histidine utilization in Pseudomonas fluorescens SBW25[J]. Genetics,2008.178:185-95.
[333]PEMBERTON, C.L., N.A. WHITEHEAD, M. SEBAIHIA, et al., Novelquorum-sensing-controlled genes in Erwinia carotovora subsp. carotovora:identification of a fungal elicitor homologue in a soft-rotting bacterium [J]. Mol PlantMicrobe Interact,2005.18:343-53.
[334]BABIC, A., A.M. GUEROUT, and D. MAZEL, Construction of an improvedRP4(RK2)-based conjugative system [J]. Res Microbiol,2008.159:545-9.
[335]LETOFFE, S., P. DELEPELAIRE, and C. WANDERSMAN, The housekeepingdipeptide permease is the Escherichia coli heme transporter and functions with twooptional peptide binding proteins [J]. Proc NatlAcad Sci U SA,2006.103:12891-6.
[336]LONE, A.G., V. DESLANDES, J.H. NASH, et al., Modulation of geneexpression in Actinobacillus pleuropneumoniae exposed to bronchoalveolar fluid [J].PLoS One,2009.4: e6139.
[337]BUETTNER, F.F., S.A. KONZE, A. MAAS, et al., Proteomic andimmunoproteomic characterization of a DIVA subunit vaccine against Actinobacilluspleuropneumoniae [J]. Proteome Sci,2011.9:23.
[338]COLEMAN, H.N., D.A. DAINES, J. JARISCH, et al., Chemically definedmedia for growth of Haemophilus influenzae strains [J]. J Clin Microbiol,2003.41:4408-10.
[339]WELCH, R.A., M.E. BAUER, A.D. KENT, et al., Battling against hostphagocytes: the wherefore of the RTX family of toxins?[J]. Infect Agents Dis,1995.4:254-72.
[340]刘金林,胸膜肺炎放线杆菌毒素ApxIV的致病性及基因缺失弱毒疫苗的研究,2009,华中农业大学.
[341]CHIEN, M.S., Y.Y. CHAN, Z.W. CHEN, et al., Actinobacilluspleuropneumoniae serotype10derived ApxI induces apoptosis in porcine alveolarmacrophages [J]. Vet Microbiol,2009.135:327-33.
[342]VANDEN BERGH, P.G., L.L. ZECCHINON, T. FETT, et al., Porcine CD18mediates Actinobacillus pleuropneumoniae ApxIII species-specific toxicity [J]. VetRes,2009.40:33.
[343]ANDERSON, T.J. and J.I. MACINNES, Expression and phylogeneticrelationships of a novel lacZ homologue from Actinobacillus pleuropneumoniae [J].FEMS Microbiol Lett,1997.152:117-23.
[344]DREYFUS, A., A. SCHALLER, S. NIVOLLET, et al., Use of recombinantApxIV in serodiagnosis of Actinobacillus pleuropneumoniae infections, developmentand prevalidation of the ApxIV ELISA[J]. Vet Microbiol,2004.99:227-38.
[345]HSU, Y.M., N. CHIN, C.F. CHANG, et al., Cloning and characterization of theActinobacillus pleuropneumoniae fur gene and its role in regulation of ApxI andAfuABC expression [J]. DNASeq,2003.14:169-81.
[346]BAUER, M.E. and R.A. WELCH, Association of RTX toxins with erythrocytes[J]. Infect Immun,1996.64:4665-72.
[347]OSICKA, R., K. PROCHAZKOVA, M. SULC, et al., A novel "clip-and-link"activity of repeat in toxin (RTX) proteins from gram-negative pathogens. Covalentprotein cross-linking by an Asp-Lys isopeptide bond upon calcium-dependentprocessing at anAsp-Pro bond [J]. J Biol Chem,2004.279:24944-56.